With 90% of Time Spent Indoors, Children and Vulnerable Groups Face Little Protection Against Pathogens or Pollutants 22/05/2026 Sophia Samantaroy Unhealthy indoor air threatens millions of lives. Public health advocates argue that investments in ventilation, air filtration, monitoring, and clean indoor air policies could deliver a rare triple benefit — protecting children’s health, strengthening pandemic preparedness, and creating healthier indoor environments well beyond the next global outbreak. Homemade air filters like the one shown here, can be crucial in preventing polluted air from entering indoor spaces during wildfires. When Georgia Lagoudas testified in front of the Rhode Island State legislature, lawmakers in the packed, poorly ventilated room were restless and unfocused. The room had already exceeded near-toxic carbon dioxide levels set by the US federal occupational health agency. At 6,000 CO2 parts per million, breathing air can lead to fatigue, headaches, reduced cognitive function, and nausea. For Lagoudas, the argument made her push for a bill on indoor air quality in schools “easy”. “All I shared was this number: 6,000,” the Brown University Pandemic Center senior fellow said. “The air quality in the room not only exceeded the health-based standard of 800 parts per million, but also the US workplace safety guidelines for acute toxicity of 5,000 parts per million.” “This was a wake-up call to turn the invisible visible,” she said. Indoor air quality is typically calibrated to odor and comfort rather than health-based metrics. The result: “When we measure indoor air quality, it’s typically poor,” said Dr Bronwyn King, a co-founder of a coalition of indoor air advocates, Air Club, and an Australian physician and entrepreneur. “It’s often filled with pathogens, pollutants like wildfire smoke, vehicle emissions, particulate matter, or toxic substances like forever chemicals, or even microplastics. All of those airborne hazards are detrimental to health.” The group’s logo, a canary, is symbolic of the “first” air pollution monitor–the canaries used in coal mines. Panelists from left: French Assembly member Emmanuel Mandon, youth advocate Katja Čič, RANI CEO Eloise Todd, Brown University senior fellow Georgia Lagoudas, CERN researcher Andre Henriques, and Air Club co-founder Dr Bronwyn King. Lagoudas, a biosecurity expert and co-founder of Air Club, spoke at a G7 event on the sidelines of the World Health Assembly, marking the culmination of a year of growing global awareness on indoor air quality sparked by a UN General Assembly meeting in New York, which drew over 300 high-level attendees. It was there that Air Club, a global coalition for indoor air, launched a high-level pledge to galvanise action around indoor air quality. France and Montenegro were the first Member States to sign. With the windows open to the Swiss mountains, the air at the indoor air quality meeting – fittingly – was crisp. Yet the reality for most buildings across the globe, far from the shores of Lake Geneva, is one of poor ventilation, air flow and contamination. A ‘paradox’: 90% of time spent indoors, with little protection Low cost air quality sensors provide crucial data to people indoors, especially in schools. People in Europe, North America, and some parts of the Middle East and East Asia spend on average 90% of their time indoors. For the past several decades, modern buildings have become increasingly energy efficient and air tight. This prolonged time spent in poorly ventilated spaces can expose people to a host of pathogens, gases like radon and carbon dioxide, and other pollutants from mold to volatile organic compounds. The consequences of breathing poor quality air, King pointed out, are numerous: lung diseases from asthma, to bronchitis and pneumonia, cancer, heart attacks, brain health and cognitive declines. “Think about how much of your everyday life is spent indoors,” said Katja Čič, a youth activist from Slovenia and International Youth Health Organization leader. “At home, school, university, or work. At the library, for groceries, cinema, shopping–all of that is indoors, and then you go back home.” “Yet sometimes the most dangerous risk is actually trapped inside with you. Fresh air literally stops at the front door,” she said. Despite the risks, indoor air quality remains largely “underestimated, insufficiently regulated, and too often absent from public debate,” said Antoine Saint-Denis, director for European and International Affairs with the French Ministry of Health. The many sources of contamination of indoor air, as listed by the US EPA. Most countries lack any form of health-based indoor air quality standards. Air Club points to five countries with the strongest, most legally-binding regulations for healthy indoor air: Belgium, South Korea, Taiwan, the UAE, and the US. About 10 other countries have some regulation or at least action plans in progress, including the UK, Germany, France, Finland, Japan, and Singapore. The paradox, Saint-Denis said, is the very luxury of living in more modern buildings with sealed windows, or driving cars sealed to the outside air, threatens the wellbeing of the millions lucky enough to afford them. “Buildings should protect us, not expose us,” Čič said. Indoor air pollution ranks third in the list of leading killers associated with poor air, behind ambient outdoor air pollution and cooking-related air pollution, which kills an estimated 2.9 million people each year. A burden on school children, other vulnerable groups Rosamund Kiss-Debrah holds a sign at a London demonstration with her daughter’s picture, Ella Roberta, who succumbed to air pollution-triggered asthma. Kissi-Debrah founded an advocacy group that fights for clean air, especially for children. Rosamund Kissi-Debrah’s daughter, Ella Roberta, was nine years old when she died from an asthma attack. Ella’s death – the first in the world to have air pollution listed as a cause – was a wake-up call to her family and her community. “Children continue to die,” said Kissi-Debrah, whose family lived in one of the most air polluted neighborhoods of South London. A city that was historically smothered with industrial smog, London became ground-zero for the advocacy work of the Ella Roberta Foundation, the organisation Kissi-Debrah launched, dedicated to cleaner air for all children. Already, London has pioneered ultra-low emission zones and electric buses across the city. She urged policymakers in the room to read her daughter’s coroner’s report outlining steps to prevent future deaths from air pollution–and offered a searing indictment of government inaction across the world. “There are solutions,” Kissi-Debrah argued. “But governments are reluctant. I’m not going to stand here and say it is easy. It is not, but we can do something about it.” Dr Bronwyn King (right) co-founded a global coalition to address indoor air quality. Her colleague Dr Andre Henriques described the live indoor air quality at the Geneva-based event. Children are especially vulnerable to the effects of air pollution – not only because their lungs are still developing, but also because of prolonged exposure, up to eight hours in poorly ventilated schools. Several policymakers pledged to raise awareness and work with their governments on indoor air quality policies following Kissi-Debrah’s intervention. But even these advocates, like French national assembly member Emmanuel Mandon, acknowledged the steep barriers to translating the scientific reality into government action. “Fragmentation is a real challenge,” Mandon said. France, which was one of the first signatories of the indoor air quality pledge, has a complex administrative system “not ideal” to take swift action, like upgrading ventilation in public transportation or providing monitoring in schools. Yet Mandon and other French delegates remained optimistic about the issue, especially as awareness grows at the highest levels of the government. “This is fundamentally a question of human dignity and equity,” said Saint-Denis, pointing to the groups subjected to the worst indoor air quality and the most vulnerable to its health effects: children in poorly ventilated schools, patients in overcrowded medical facilities, workers in toxic indoor environments, prisoners, and the socioeconomically vulnerable in poor housing. “They are also frequently the least protected and the least able to take control of the environment that they are in,” said Jane Hulton, CEO of Coalition for Epidemic Preparedness Innovations (CEPI). A matter of biosecurity and pandemic preparedness Airborne infectious disease outbreaks, like that of hantavirus on the cruise ship Hondius, rapidly spread unchecked in poorly ventilated indoor spaces. An underappreciated aspect in the fight for clean indoor air is its potential to mitigate the spread of airborne pathogens. Around 15% of the air inhaled in an indoor space is the spent breath of another person. So with highly infectious airborne diseases such as coronaviruses, measles, or influenza, the risk of becoming sick is much higher indoors. The COVID-19 pandemic accelerated calls for better ventilation and monitoring, especially as buildings like schools, churches, and hospitals became hotspots for transmission. Halton called awareness of the dangers of indoor air contamination a lesson “learned too late”, recalling that transmission was “especially efficient indoors in poorly ventilated spaces”. Her organization, launched in the wake of the deadly 2014-16 Ebola outbreaks, aims to rapidly produce vaccines against pandemic threats. She sees improving indoor air quality as a crucial step in buying time to deploy vaccines and other medical countermeasures. CEPI’s 100-day mission, which would deliver a vaccine ready for manufacturing at scale within 100 days of identifying a new pandemic threat, is contingent upon preventing widespread transmission in the first 10 days, Halton said. “If we can’t prevent transmission in those first 10 days, we’ve exacerbated the problem.” Biosecurity experts often draw parallels as to how the fight to eliminate water-borne pathogens came not through vaccines, but through infrastructure–water filtration and sanitation. “The lesson is broader than any one disease,” Halton said. “How we manage indoor air matters for preparedness, resilience, and health security across all manner of threats and risks. Taking a breath in a poorly managed indoor environment actually can amplify a biological risk.” Progess in Montenegro, France, patchwork of US states The experts, advocates, and policymakers gathered at the Geneva Health Forum to discuss solutions to improve indoor air quality. Lagoudas’s work led her to champion indoor air policies across the US and to collaborate with an unlikely ally – the government of Montenegro. The Adriatic coastal nation has begun installing air purifiers, windows that open and close, and energy efficient ventilators–machines that bring in outdoor air, filter it, and then either heat or cool it, Lagoudas explained. Its government has also launched efforts to monitor air quality in school buildings. While it is fairly common now to be able to check the levels of outdoor air, information of indoor air is much harder to come by. In the past decade, advancements in small, affordable air monitors have empowered everyday citizens to track their indoor air, providing crucial real-time monitoring for health awareness. France, meanwhile, is at the forefront of global indoor air quality advocacy, outlining actions through their IAQ observatory and their requirements for schools and elder care facilities. Lagoudas and the Air Club have also worked with Montenegro to advance what they term “durable policy solutions”– measures that would outlast political changes or sentiments. Closer to home, at least a dozen US states have passed laws to advance indoor air quality, “which is actually quite remarkable,” Lagoudas said. These state-level actions have typically taken the form of one of four solutions: classroom air quality monitoring, building ventilation assessment, program funding and public data sharing, and the designation of “who’s in charge” in the form of a task force or council to take action. This “decentralized”, patchwork approach means that very few states have implemented all four of the measures, but it nevertheless provides “it provides a great foundation” for future action, Lagoudas said. California requires indoor CO2 monitoring and assessments in schools receiving grants for infrastructure improvement. Connecticut also has stringent indoor air quality legislation. Other states, like Arizona, Illinois, and Massachusetts, have legislation in the books, though most states, at a bare minimum, address radon testing and carbon monoxide alarms. The North Star, she hopes, is federal legislation to keep school children safe across the United States – even as US public health infrastructure is “torn apart” by the Trump administration. The benefits to children in schools, in particular, spur indoor air quality advocates forward. “Healthy indoor air is actually not a niche issue,” Halton said. “It’s a core public health infrastructure issue.” Image Credits: S. Samantaroy/HPW, Koby Levin/Outlier Media, Tim Witzdam , US EPA, Ella Roberta Foundation, Franklin Braeckman/Oceanwide Expeditions . UN Backs Landmark ICJ Climate Crisis Ruling, Defying US and Petrostates 22/05/2026 Stefan Anderson The UN General Assembly voted 141-8 to endorse a landmark International Court of Justice opinion finding that states are bound under international law to curb greenhouse gas emissions driving the climate crisis and protect states most affected by its fallout. “Climate change is an unprecedented challenge of civilisational proportions,” the resolution states. “The well-being of present and future generations of humankind depends on our immediate and urgent response to it.” Thursday’s historic vote was opposed by many of the world’s largest fossil fuel producers, reflecting the growing distance between nations fuelling the climate crisis and the vulnerable countries and people facing the brunt of its floods, droughts and extreme weather. Voting against were Belarus, Iran, Israel, Liberia, Russia, Saudi Arabia, the United States and Yemen — a coalition of major oil and gas producers, sanctioned states, and close US allies. “The world’s highest court has spoken. Today, the General Assembly has answered,” UN Secretary-General Antonio Guterres said, calling the vote “a powerful affirmation of international law, climate justice, science and the responsibility of states to protect people from the escalating climate crisis.” Abstaining were a bloc of 28 countries spanning emerging emitters and traditional petrostates, including India, Iraq, Kuwait, Qatar, Nigeria, the Czech Republic and Turkey, which will host COP31 in November. The 141 in favour included Australia, Canada, China, France, Germany, Japan, the United Arab Emirates and the United Kingdom — wealthy historic emitters and current fossil fuel exporters now formally on record backing the court’s findings. “Those least responsible for climate change are paying the highest price,” Guterres added. “That injustice must end.” Youth wins 🇻🇺 @VanuatuUN Ambassador, @odo_tevi, is opening the session with a powerful statement: "The credibility of this institution is at stake today […] This day will be remembered. It will be remembered as the moment the UN decided what to do with the @CIJ_ICJ climate ruling." pic.twitter.com/jgMcY0jmkw — Center for International Environmental Law (@ciel_tweets) May 20, 2026 For Vanuatu, the low-lying Pacific island nation that filed the original case at the ICJ and championed Thursday’s resolution, the vote was the culmination of a seven-year diplomatic campaign aimed at putting climate change inside the framework of binding international law. The path from the ICJ to the General Assembly traces back to a 2019 campaign by 27 law students at the University of the South Pacific in Vanuatu’s capital, Port Vila, who lobbied Pacific governments to take the climate crisis to the world’s top international court. Vanuatu took up the cause in 2021 and led an 18-month diplomatic push that resulted in the General Assembly’s unanimous request for an advisory opinion in March 2023. The UN court’s unanimous ruling, issued in July last year, capped the most participated advisory case in the ICJ’s history, with 96 states and 11 international organisations taking part in oral hearings, alongside a record 91 written submissions. Leaders of the student campaign celebrated Thursday’s General Assembly victory, with Vishal Prasad, director of the Pacific Islands Students Fighting Climate Change, calling it “a turning point in accountability for damaging the climate.” “The journey of this idea from classrooms in the Pacific to The Hague and the United Nations gives us continued hope that when people organise, the world can be moved to act,” Prasad said. “Communities on the frontlines, like in the Pacific, have been waiting far too long and continue to pay too high a price for the actions of others.” Paris, renewables, and responsibility Thursday’s resolution proposes a series of measures to meet the ICJ’s legal obligations, drawing on mainstays of UN climate negotiations. It calls on all states to comply with the ICJ opinion by “preventing significant harm to the environment by acting with due diligence” and “using all means at their disposal to prevent activities carried out within their jurisdiction or control from causing significant harm to the climate system.” The resolution recalls the court’s finding that a breach of those obligations is “an internationally wrongful act” that can require the responsible state to provide “full reparation to injured States in the form of restitution, compensation and satisfaction.” It urges states to implement the Paris Agreement’s 1.5 degrees Celsius temperature goal, including by “tripling renewable energy capacity and doubling the global average annual rate of energy efficiency improvements by 2030, transitioning away from fossil fuels in energy systems in a just, orderly and equitable manner and so as to reach net zero by 2050.” The resolution further calls for the phase-out of “inefficient fossil fuel subsidies that do not address energy poverty or just transitions as soon as possible.” “At a time when fragmentation between nations feels more visible than ever, the UN resolution endorsing the ICJ climate ruling offers a renewed path for international cooperation,” said Camille Cortez, senior campaigner on climate justice at Amnesty International. “Fossil fuel infrastructure alone poses risks for the health and livelihoods of at least 2 billion people globally, roughly a quarter of the world’s population,” she added. “This new UN resolution paves the way for governments to show they stand for climate justice and has the potential to shape global climate accountability for years to come.” ‘So-called’ obligations US ambassador to the United Nations, Tammy Bruce, dismissed the legitimacy of the UN court ruling. The resolution drew sharp opposition from Washington, which led the small bloc voting against the text and used its floor time to challenge the legal foundations of the court’s ruling. US Ambassador to the UN Tammy Bruce, a former Fox News host, called the resolution “highly problematic,” dismissing the “so-called ‘obligations'” contained in the ICJ’s advisory ruling. The United States, Bruce said, had opposed seeking an opinion from the UN court in the first place. “Throughout the negotiation of this resolution, the United States has been consistent in conveying our opposition to this initiative,” Bruce told the assembly. “This resolution is highly problematic in calling on States to comply with so-called ‘obligations’ that are based on non-binding conclusions of the Court on which UN Member States’ views diverge.” While the Hague-based ICJ’s rulings are not legally binding, they carry significant symbolic weight and are frequently used to substantiate legal arguments in national courts. The July 2025 opinion is already being woven into climate litigation around the world, with judges starting to cite it in their rulings. While Washington “understands the concerns that Vanuatu and other countries have about specific environmental threats and the importance they attach to the Court’s opinion,” Bruce said, the resolution “improperly treats the Court’s opinion as irrefutably authoritative and as setting out binding obligations on States.” The resolution also “amplifies legal errors from the Court’s opinion,” Bruce added, arguing the duty to prevent transboundary climate harm “would impermissibly interfere with each State’s sovereign rights to regulate and manage its own energy policy.” “The opinion does not invent new law; it clarifies the law that already binds us,” said Odo Tevi, Vanuatu’s UN ambassador. “The ruling matters because the harm is real, and it is already here — for low-lying islands and coastlines, for communities facing drought and failed harvests, for people whose homes, livelihoods and cultures are being reshaped by forces they did nothing to set in motion.” Saudi Arabia, which sided with the US against the resolution, called the inclusion of any reference to the ICJ’s opinion in negotiating texts at the last UN climate summit, COP30 in Belem, a “deep, deep, deep red line.” That dynamic now sets the stage for COP31 in Antalya in November, where Turkey — among Thursday’s abstainers — will preside over talks already shadowed by the collapse of fossil fuel language at the previous summit. With the Arab Group, Russia and the United States lined up against the court’s findings, and key emerging emitters refusing to back them, the path to translating Thursday’s legal victory into meaningful diplomatic outcomes looks steep. “Climate change is an existential problem of planetary proportions that imperils all forms of life and the very health of our planet,” Guyana’s representative said, speaking on behalf of the Caribbean region. “It is crucial that we not only welcome the opinion in this moment but also ensure meaningful follow-up.” Image Credits: UN, Gage Skidmore. Polio Eradication Needs Political Commitment as Conflict Makes Vaccination ‘Impossible’ in Areas Like North Yemen 21/05/2026 Disha Shetty Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. The world is in the last stretch of polio eradication, but closing this gap will require political commitment, the World Health Organization (WHO) told member states at the ongoing 79th session of the World Health Assembly (WHA). Polio virus has shown resurgence in conflict-hit or hard-to-reach areas like northern Yemen, Gaza, Afghanistan, and Pakistan. Conflict has limited access in some of these areas and made vaccination campaigns near impossible in others. “We are closer to polio eradication than ever, but the final stretch demands exceptional operational discipline and sustained political commitment. The remaining reservoirs are the hardest to access, the most politically complex, and the most unforgiving of operational gaps,” said Dr Hanan Balkhy, WHO regional director for the Eastern Mediterranean Regional Office (EMRO). WHO said that the support of every member country and the collective political will have brought the world to the brink of success. “The gaps mostly are in the political web, gaps in vaccination coverage, where children are still being missed, gaps in access, where insecurity and instability limit our reach, and gaps in financing, where resources must match the urgency of the final push,” said Dr Razia Pendse, WHO Chef de Cabinet. Wild polio transmission is declining Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean Regional Office (EMRO). Even in areas where the polio cases are endemic, there are showing positive signs of decline. Afghanistan and Pakistan reported 99 wild polio cases in 2024, 52 in 2025 and just six as of May 2026. “Transmission is now limited to a small number of high-risk areas, particularly along cross border corridors between the two countries,” Balkhy said. While the two countries are coordinating for vaccination campaigns, there are still children going without vaccinations in the southern Khyber Pakhtunkhwa region of Pakistan. WHO said it has managed to vaccinate nearly 600,000 children in Gaza, averting a larger polio outbreak. Egypt too managed to successfully interrupt the transmission of the virus with vaccination campaigns which WHO highlighted as an example of a successful result when the political will exists. Northern Yemen is completely out of reach WHO has been unable to conduct vaccination campaigns in conflict-hit northern Yemen. In northern Yemen, an outbreak has paralysed 450 children. “Most of them in the northern governance, where no mass vaccination campaign has been possible since 2022, and we continue to try. I urge member states to continue raising the need for access as a priority in northern Yemen,” Balkhy said. Yemen had been polio-free since the year 2006. Balkhy assured that the WHO is pushing for improved access for polio eradication campaigns, and asked others to do so as well. Canada highlighted the important role of the health workers against such a harsh backdrop. “The tireless efforts of frontline health workers, the majority of whom were women, made this achievement possible. We want to highlight the challenging context in which these health workers perform their duty every day, in some cases at risk to their personal safety,” Canada’s representative told WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Access and funding challenges The 79th World Health Assembly in session. Unpredictable funding is getting in the way of the polio eradication campaign. The campaigns have been plagued by funding challenges, and the gap is a whopping $2.3 billion. “Several countries, including Iraq, Libya, and Syria have already transitioned polio functions to domestic financing, demonstrating that polio infrastructure, when embedded in health systems, delivers lasting returns,” Balkhy said, citing examples of countries that have become self-reliant. The global vaccine alliance, Gavi, has urged countries to use an integrated approach to reach zero-dose children with vaccination and primary health care, especially in humanitarian settings and emergencies. It assured countries of its continued support. It is an approach that Japan too supported, adding that the country, “will continue to work in collaboration with WHO and other relevant organizations to contribute to polio eradication and to sustaining a polio-free world beyond eradication.” “To finally end polio, we must sustain access, close funding gaps, maintain operational discipline, and reach every last child. If we do that, and I’m pretty sure we will finish this job,” Balkhy said. Image Credits: WHO, WHO Yemen, X/WHO. Restore Funds for Malaria, Africa Urges 21/05/2026 Kerry Cullinan Nigeria, on behalf of African states, called for more investment in malaria. The African region made an impassioned appeal for global funding to be restored for malaria elimination at the World Health Assembly on Wednesday. Drastic aid cuts in the past 18 months, particularly by the United States, have had a dramatic effect on malaria efforts – particularly as they coincide with growing drug resistance. Nigeria, speaking for African member states, noted that the World Health Organization’s (WHO) malaria elimination effort known as E-2025 has not been funded since 2024. The initiative had focused on supporting 25 countries with the potential to eliminate malaria by 2025 with Global Fund money. Around 95% of global malaria cases are in Africa, and Nigeria is the worst-affected country in the world, accounting for almost a quarter of the world’s malaria cases and a third of all deaths. It requested the assembly to “restore financing for malaria elimination, including the E 2025 initiative, and accelerate roll out of the RTS,S (Mosquirix) and R21 (Matrix-M) vaccines”. Instead of being on track to meet the Sustainable Development Goal target of reducing malaria cases by 90% by 2030, global incidence has risen by 8.5%, according to the WHO’s World Health Statistics 2026. Millions of lives at risk In mid-2025, the WHO warned that funding cuts to malaria programmes put “millions of additional lives at risk and could reverse decades of progress”. Between 2010 and 2023, the US contributed around 37% of global malaria financing. By early April 2025, more than 40% of planned distribution of insecticide-treated nets (ITNs) – the cornerstone of malaria prevention – were delayed, according to data provided by national malaria programmes. “Nearly 30% of seasonal malaria chemoprevention (SMC) campaigns to protect 58 million children were also off track,” the WHO reported. Angola told the WHA that malaria is one of its leading causes of morbidity and mortality, yet its efforts to address the disease were being hampered by “climate-related vulnerabilities and declining external financing”. Several other countries mentioned changing climate was increasing their vulnerability to malaria. On a positive note, Cabo Verde became the first sub-Saharan country in 50 years to be certified malaria-free. Suriname, which used to have the highest annual malaria incidence in the Amazon region, has also received the WHO malaria elimination certification. Suriname said its success relied on two critical pillars: decentralised primary health care and the rollout of rapid diagnostic tests and artemisinin-based combination therapy. Malaysia, which aims to be malaria-free by 2030, asked for more WHO support. New plan for tuberculosis The assembly endorsed a decision requesting the Director-General to develop a post-2030 tuberculosis (TB) strategy for the 2028 WHA. Poland reminded the assembly that tuberculosis remains “one of the world’s deadliest infectious diseases, despite being preventable and curable”. Its own TB response had been challenged by “the influx of refugees from Ukraine after 2022”, which it addressed by “flexible, patient-centred, and community-based care”. Poland’s contribution to the post 2030 TB strategy has been focused on drug-resistant TB, migration-sensitive approaches, patient-centred care, and health system resilience. “On tuberculosis, our region is outpacing the world. Incidence is down 28% and mortality down 46% since 2015, and we lead globally on TB-HIV integration,” said Nigeria. Nigeria also noted that 23 African countries have eliminated at least one neglected tropical disease, while vaccination had averted 1.9 million deaths in 2024. “These gains share the same ingredients: political leadership, integrated systems, mobilised communities, and partners align behind one national plan, but they are fragile. “Our region still carries 95% of the global malaria burden. Ten countries account for 80% of zero-dose children. We hold 17% of the world’s 30 high-burden TB countries. “Our frameworks are sound. What is missing is the financing, the integration and the accountability to match them.” World Health Assembly Condemns Iranian Strikes on Gulf States, Health Fallout of Hormuz Closure 21/05/2026 Stefan Anderson The 79th World Health Assembly in session. GENEVA – The World Health Assembly (WHA) voted 91-2 to adopt a resolution condemning Iranian attacks on civilian infrastructure across Gulf countries amid its war with the United States and Israel. The resolution condemns “in the strongest terms” the Iranian attacks on civilians and civilian objects in Gulf states and Jordan, citing damage to “medical and healthcare facilities, water desalination plants, energy facilities, airports and ports.” It further calls on member states to safeguard health system continuity and address disruptions to maritime routes, “including through the Strait of Hormuz, in order to safeguard global health supply chains.” Support for the resolution, spearheaded by the states of the Gulf Cooperation Council (GCC) and Jordan, included every country in the Middle East excluding Iran, all European Union Members, and Ukraine, which has rallied alongside Gulf states due to Iran’s role in supplying drones used by Russia to invade its skies. “These public health consequences addressed in this resolution clearly fall within the mandate of the WHO, and it focuses exclusively on the public health consequences and humanitarian locations resulting from their terrorist Iranian attacks,” the United Arab Emirates said following the vote. Iran was joined only by Nicaragua in opposition. WHA79 voting on the resolution on Iran’s attacks on the Gulf states. “These attacks also have health implications at the global level,” the UAE added. “As we’ve seen from Iran’s disruption of the Strait of Hormuz, and to the essential lifelines for the delivery of medicines, vaccines, medical products, essential health commodities, food, and fuel, all of which are necessary for the functioning of health systems.” The Iranian delegation described the resolution as applying “a selective use of international law”, which it called “inconsistent with the technical, evidence-based and impartial character of this organisation” and setting “a dangerous precedent that risks eroding the main objective and functions” of the WHO. “The proposed text deliberately ignores severe damages inflicted on Iran’s own health infrastructure as a result of military actions in the region,” its delegate said. “It fails to acknowledge the root causes of the current situation, including provocations and aggressions that compel defensive responses while presenting a distorted and incomplete picture of events.” The resolution asks WHO Director-General Dr Tedros Adhanom Ghebreyesus to deliver two reports to next year’s WHA: a global assessment of how Hormuz disruptions and rising energy and transport costs are affecting access to medicines, vaccines and essential health commodities in low- and middle-income countries, and a separate report on the mental health toll of the Iranian attacks and on supply-chain delays for humanitarian medical deliveries. “We are deeply concerned by the suffering of civilians and the destruction of health systems, civilian infrastructure, and supply chains,” Indonesia’s delegation said. “The destruction is profound, but it has not fallen equally across the region. A credible public health response is possible only when all parties cease hostilities and return to the path of diplomacy.” Notable abstentions Thirty-one countries abstained, including Switzerland, Mexico, Russia, South Africa, Brazil, China, Indonesia and Malaysia. China described the Iranian crisis as “one of the most urgent challenges” faced by the international community – and became the only country in the assembly to address the US-sized elephant in the room. “The root cause of this crisis is that an individual country, without the Security Council’s authorisation, has flagrantly launched a military attack on Iran, which seriously violates the basic norms governing international relations based on the principles of the UN charter,” China said. “WHO’s response should follow the principles of objectivity, neutrality, and professionalism, which will help de-escalate the situation rather than aggravating tensions.” South Africa, acknowledging the severe threat of rising energy, fertilizer and seed costs on the livelihoods of people on the African continent in particular, struck a similar middle-ground, noting that while there can be “no military solution” to the war, its “root causes cannot be ignored.” “We have spoken out against attacks on all sides of the conflict. The ravages of the conflict across the region must be acknowledged, as we cannot afford to create a hierarchy of victims,” said South Africa. Strait of Hormuz supply shocks The resolution takes particular aim at the continued de facto closure of the Strait of Hormuz, which has seriously disrupted supply chains for life-saving medicines, food, fertiliser, fuel and commodities on which health systems and the livelihoods of civilian populations depend. “The continued closure of the Strait of Hormuz remains a critical pressure point, disrupting global supply chains and increasing the cost of essential medical commodities,” said WHO Assistant Director-General Dr Chikwe Ihekweazu. “Humanitarian settings are already experiencing funding shortages, now further compounded by fuel, food, and medicine costs.” Several countries in the midst of intense conflicts worsened by the closure of the Strait, including Sudan, Somalia and Yemen, joined the resolution as co-authors. None of the three currently holds voting powers at the WHO due to unpaid membership dues. “The de facto closure of the Strait of Hormuz has only compounded the impacts on already devastated healthcare systems in some of the most vulnerable humanitarian contexts in the world, from Sudan to Gaza,” the UK delegation said. “The delayed supply of medicines and vaccines, and the increasing fuel costs, are reducing the reliability of essential services.” Both the US and Iran blame the closure on one another. Iran has turned the Strait into a minefield and begun enforcing a tiered system of checkpoints and fees, and the US military continues to enforce a blockade on vessels bound for Iran. Countries on both sides of the resolution vote reaffirmed the importance of opening the Strait. Healthcare is a war target now The resolution’s focus on the security of medical personnel and facilities reflects growing concern about the dark tide of violence against health workers and facilities that has come to define modern conflicts. “It cannot be emphasised enough that civilian healthcare personnel, hospitals, and medical facilities must be respected and protected at all times in accordance with international humanitarian law,” Malaysia’s delegate said. Attacks on hospitals, once cause for severe international reckoning and condemnation, are now routine in wars around the globe. Healthcare – in current wars – is now a target. Russian strikes on Ukrainian healthcare since the start of its full-scale invasion surpassed the 3,000 mark earlier this month. In Gaza, WHO has confirmed 2,148 attacks on healthcare since the war began, resulting in 1,048 deaths – destruction so complete UN Special Rapporteurs call it a “medicide”. Amid Sudan’s brutal civil war, the violence inflicted on medical facilities and personnel – particularly in the throws the ongoing genocide in Darfur – is equally extreme, with WHO confirming at least 2,052 deaths. No healthcare strikes While Iran has launched hundreds of missile and drone strikes throughout the region – hitting residential buildings, desalination plants, energy infrastructure, hotels, airports, embassies and other civilian targets, resulting in 41 deaths – no direct attacks on healthcare against Gulf States or Jordan have been documented in the WHO’s Surveillance System for Attacks on Healthcare (SSA) database. Independent global verification authorities, including conflict monitor ACLED and Human Rights Watch, equally list no attacks on healthcare in Gulf countries by Iran’s strikes, out of 660 listed. Israeli health facilities have been hit nine times by Iranian attacks. No deaths or injuries occurred as a result of those strikes, according to WHO data. However, Iranian strikes have repeatedly hit desalination plants, the foundation of clean water systems in the Gulf. Another attack set a fire outside the UAE’s largest nuclear power plant, raising fears it could be targeted again. “Several Gulf countries rely on desalination for 70 to 90% of safe water supplies, making these systems both essential and highly vulnerable,” said Dr Hanan Balky, WHO’s Eastern Mediterranean regional director. “Damage to energy and desalination infrastructure carry major public health risks, including worsening air pollution, disruption to safe water supply and sanitation, and reduced continuity of essential health services.” Resolution from Iran defeated On Tuesday, Lebanon received overwhelming support from the majority of member states in the wake of Israeli attacks on its health infrastructure. Ninety-five member states voted in favour of a resolution that noted “a health emergency in Lebanon resulting from ongoing and recently intensified hostilities” and called for “the full protection of healthcare in Lebanon, including patients, health personnel, facilities and transport”. Only Israel and Honduras opposed the resolution, which did not name Israel as the aggressor. SSA documents 170 attacks on health infrastructure in Lebanon, resulting in 116 deaths of medical personnel and patients. Israeli strikes so far have killed around 2,700 people. “Millions of people have been displaced, approximately 3.2 million internally displaced people in the Islamic Republic, and one million in Lebanon,” Ihekweazu said, citing IOM figures. Meanwhile, the SSA has confirmed 32 attacks on Iranian health facilities since the onset of the violence, resulting in 12 deaths. The US and Israel have launched thousands of bombs across the country, killing a total of at least 3,375 people. However, during the same debate on Tuesday, Iran’s resolution, condemning recent attacks on its patients and health infrastructure, including on the Pasteur Institute, was defeated. Only 19 countries supported Iran, 30 voted against, and a whopping 58 countries abstained. Several countries cited Iran’s attacks against its own citizens and Gulf states, and the blockade of the Strait of Hormuz, preventing the flow of medical supplies, as reasons for not supporting the resolution. Image Credits: X/WHO. EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UN Backs Landmark ICJ Climate Crisis Ruling, Defying US and Petrostates 22/05/2026 Stefan Anderson The UN General Assembly voted 141-8 to endorse a landmark International Court of Justice opinion finding that states are bound under international law to curb greenhouse gas emissions driving the climate crisis and protect states most affected by its fallout. “Climate change is an unprecedented challenge of civilisational proportions,” the resolution states. “The well-being of present and future generations of humankind depends on our immediate and urgent response to it.” Thursday’s historic vote was opposed by many of the world’s largest fossil fuel producers, reflecting the growing distance between nations fuelling the climate crisis and the vulnerable countries and people facing the brunt of its floods, droughts and extreme weather. Voting against were Belarus, Iran, Israel, Liberia, Russia, Saudi Arabia, the United States and Yemen — a coalition of major oil and gas producers, sanctioned states, and close US allies. “The world’s highest court has spoken. Today, the General Assembly has answered,” UN Secretary-General Antonio Guterres said, calling the vote “a powerful affirmation of international law, climate justice, science and the responsibility of states to protect people from the escalating climate crisis.” Abstaining were a bloc of 28 countries spanning emerging emitters and traditional petrostates, including India, Iraq, Kuwait, Qatar, Nigeria, the Czech Republic and Turkey, which will host COP31 in November. The 141 in favour included Australia, Canada, China, France, Germany, Japan, the United Arab Emirates and the United Kingdom — wealthy historic emitters and current fossil fuel exporters now formally on record backing the court’s findings. “Those least responsible for climate change are paying the highest price,” Guterres added. “That injustice must end.” Youth wins 🇻🇺 @VanuatuUN Ambassador, @odo_tevi, is opening the session with a powerful statement: "The credibility of this institution is at stake today […] This day will be remembered. It will be remembered as the moment the UN decided what to do with the @CIJ_ICJ climate ruling." pic.twitter.com/jgMcY0jmkw — Center for International Environmental Law (@ciel_tweets) May 20, 2026 For Vanuatu, the low-lying Pacific island nation that filed the original case at the ICJ and championed Thursday’s resolution, the vote was the culmination of a seven-year diplomatic campaign aimed at putting climate change inside the framework of binding international law. The path from the ICJ to the General Assembly traces back to a 2019 campaign by 27 law students at the University of the South Pacific in Vanuatu’s capital, Port Vila, who lobbied Pacific governments to take the climate crisis to the world’s top international court. Vanuatu took up the cause in 2021 and led an 18-month diplomatic push that resulted in the General Assembly’s unanimous request for an advisory opinion in March 2023. The UN court’s unanimous ruling, issued in July last year, capped the most participated advisory case in the ICJ’s history, with 96 states and 11 international organisations taking part in oral hearings, alongside a record 91 written submissions. Leaders of the student campaign celebrated Thursday’s General Assembly victory, with Vishal Prasad, director of the Pacific Islands Students Fighting Climate Change, calling it “a turning point in accountability for damaging the climate.” “The journey of this idea from classrooms in the Pacific to The Hague and the United Nations gives us continued hope that when people organise, the world can be moved to act,” Prasad said. “Communities on the frontlines, like in the Pacific, have been waiting far too long and continue to pay too high a price for the actions of others.” Paris, renewables, and responsibility Thursday’s resolution proposes a series of measures to meet the ICJ’s legal obligations, drawing on mainstays of UN climate negotiations. It calls on all states to comply with the ICJ opinion by “preventing significant harm to the environment by acting with due diligence” and “using all means at their disposal to prevent activities carried out within their jurisdiction or control from causing significant harm to the climate system.” The resolution recalls the court’s finding that a breach of those obligations is “an internationally wrongful act” that can require the responsible state to provide “full reparation to injured States in the form of restitution, compensation and satisfaction.” It urges states to implement the Paris Agreement’s 1.5 degrees Celsius temperature goal, including by “tripling renewable energy capacity and doubling the global average annual rate of energy efficiency improvements by 2030, transitioning away from fossil fuels in energy systems in a just, orderly and equitable manner and so as to reach net zero by 2050.” The resolution further calls for the phase-out of “inefficient fossil fuel subsidies that do not address energy poverty or just transitions as soon as possible.” “At a time when fragmentation between nations feels more visible than ever, the UN resolution endorsing the ICJ climate ruling offers a renewed path for international cooperation,” said Camille Cortez, senior campaigner on climate justice at Amnesty International. “Fossil fuel infrastructure alone poses risks for the health and livelihoods of at least 2 billion people globally, roughly a quarter of the world’s population,” she added. “This new UN resolution paves the way for governments to show they stand for climate justice and has the potential to shape global climate accountability for years to come.” ‘So-called’ obligations US ambassador to the United Nations, Tammy Bruce, dismissed the legitimacy of the UN court ruling. The resolution drew sharp opposition from Washington, which led the small bloc voting against the text and used its floor time to challenge the legal foundations of the court’s ruling. US Ambassador to the UN Tammy Bruce, a former Fox News host, called the resolution “highly problematic,” dismissing the “so-called ‘obligations'” contained in the ICJ’s advisory ruling. The United States, Bruce said, had opposed seeking an opinion from the UN court in the first place. “Throughout the negotiation of this resolution, the United States has been consistent in conveying our opposition to this initiative,” Bruce told the assembly. “This resolution is highly problematic in calling on States to comply with so-called ‘obligations’ that are based on non-binding conclusions of the Court on which UN Member States’ views diverge.” While the Hague-based ICJ’s rulings are not legally binding, they carry significant symbolic weight and are frequently used to substantiate legal arguments in national courts. The July 2025 opinion is already being woven into climate litigation around the world, with judges starting to cite it in their rulings. While Washington “understands the concerns that Vanuatu and other countries have about specific environmental threats and the importance they attach to the Court’s opinion,” Bruce said, the resolution “improperly treats the Court’s opinion as irrefutably authoritative and as setting out binding obligations on States.” The resolution also “amplifies legal errors from the Court’s opinion,” Bruce added, arguing the duty to prevent transboundary climate harm “would impermissibly interfere with each State’s sovereign rights to regulate and manage its own energy policy.” “The opinion does not invent new law; it clarifies the law that already binds us,” said Odo Tevi, Vanuatu’s UN ambassador. “The ruling matters because the harm is real, and it is already here — for low-lying islands and coastlines, for communities facing drought and failed harvests, for people whose homes, livelihoods and cultures are being reshaped by forces they did nothing to set in motion.” Saudi Arabia, which sided with the US against the resolution, called the inclusion of any reference to the ICJ’s opinion in negotiating texts at the last UN climate summit, COP30 in Belem, a “deep, deep, deep red line.” That dynamic now sets the stage for COP31 in Antalya in November, where Turkey — among Thursday’s abstainers — will preside over talks already shadowed by the collapse of fossil fuel language at the previous summit. With the Arab Group, Russia and the United States lined up against the court’s findings, and key emerging emitters refusing to back them, the path to translating Thursday’s legal victory into meaningful diplomatic outcomes looks steep. “Climate change is an existential problem of planetary proportions that imperils all forms of life and the very health of our planet,” Guyana’s representative said, speaking on behalf of the Caribbean region. “It is crucial that we not only welcome the opinion in this moment but also ensure meaningful follow-up.” Image Credits: UN, Gage Skidmore. Polio Eradication Needs Political Commitment as Conflict Makes Vaccination ‘Impossible’ in Areas Like North Yemen 21/05/2026 Disha Shetty Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. The world is in the last stretch of polio eradication, but closing this gap will require political commitment, the World Health Organization (WHO) told member states at the ongoing 79th session of the World Health Assembly (WHA). Polio virus has shown resurgence in conflict-hit or hard-to-reach areas like northern Yemen, Gaza, Afghanistan, and Pakistan. Conflict has limited access in some of these areas and made vaccination campaigns near impossible in others. “We are closer to polio eradication than ever, but the final stretch demands exceptional operational discipline and sustained political commitment. The remaining reservoirs are the hardest to access, the most politically complex, and the most unforgiving of operational gaps,” said Dr Hanan Balkhy, WHO regional director for the Eastern Mediterranean Regional Office (EMRO). WHO said that the support of every member country and the collective political will have brought the world to the brink of success. “The gaps mostly are in the political web, gaps in vaccination coverage, where children are still being missed, gaps in access, where insecurity and instability limit our reach, and gaps in financing, where resources must match the urgency of the final push,” said Dr Razia Pendse, WHO Chef de Cabinet. Wild polio transmission is declining Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean Regional Office (EMRO). Even in areas where the polio cases are endemic, there are showing positive signs of decline. Afghanistan and Pakistan reported 99 wild polio cases in 2024, 52 in 2025 and just six as of May 2026. “Transmission is now limited to a small number of high-risk areas, particularly along cross border corridors between the two countries,” Balkhy said. While the two countries are coordinating for vaccination campaigns, there are still children going without vaccinations in the southern Khyber Pakhtunkhwa region of Pakistan. WHO said it has managed to vaccinate nearly 600,000 children in Gaza, averting a larger polio outbreak. Egypt too managed to successfully interrupt the transmission of the virus with vaccination campaigns which WHO highlighted as an example of a successful result when the political will exists. Northern Yemen is completely out of reach WHO has been unable to conduct vaccination campaigns in conflict-hit northern Yemen. In northern Yemen, an outbreak has paralysed 450 children. “Most of them in the northern governance, where no mass vaccination campaign has been possible since 2022, and we continue to try. I urge member states to continue raising the need for access as a priority in northern Yemen,” Balkhy said. Yemen had been polio-free since the year 2006. Balkhy assured that the WHO is pushing for improved access for polio eradication campaigns, and asked others to do so as well. Canada highlighted the important role of the health workers against such a harsh backdrop. “The tireless efforts of frontline health workers, the majority of whom were women, made this achievement possible. We want to highlight the challenging context in which these health workers perform their duty every day, in some cases at risk to their personal safety,” Canada’s representative told WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Access and funding challenges The 79th World Health Assembly in session. Unpredictable funding is getting in the way of the polio eradication campaign. The campaigns have been plagued by funding challenges, and the gap is a whopping $2.3 billion. “Several countries, including Iraq, Libya, and Syria have already transitioned polio functions to domestic financing, demonstrating that polio infrastructure, when embedded in health systems, delivers lasting returns,” Balkhy said, citing examples of countries that have become self-reliant. The global vaccine alliance, Gavi, has urged countries to use an integrated approach to reach zero-dose children with vaccination and primary health care, especially in humanitarian settings and emergencies. It assured countries of its continued support. It is an approach that Japan too supported, adding that the country, “will continue to work in collaboration with WHO and other relevant organizations to contribute to polio eradication and to sustaining a polio-free world beyond eradication.” “To finally end polio, we must sustain access, close funding gaps, maintain operational discipline, and reach every last child. If we do that, and I’m pretty sure we will finish this job,” Balkhy said. Image Credits: WHO, WHO Yemen, X/WHO. Restore Funds for Malaria, Africa Urges 21/05/2026 Kerry Cullinan Nigeria, on behalf of African states, called for more investment in malaria. The African region made an impassioned appeal for global funding to be restored for malaria elimination at the World Health Assembly on Wednesday. Drastic aid cuts in the past 18 months, particularly by the United States, have had a dramatic effect on malaria efforts – particularly as they coincide with growing drug resistance. Nigeria, speaking for African member states, noted that the World Health Organization’s (WHO) malaria elimination effort known as E-2025 has not been funded since 2024. The initiative had focused on supporting 25 countries with the potential to eliminate malaria by 2025 with Global Fund money. Around 95% of global malaria cases are in Africa, and Nigeria is the worst-affected country in the world, accounting for almost a quarter of the world’s malaria cases and a third of all deaths. It requested the assembly to “restore financing for malaria elimination, including the E 2025 initiative, and accelerate roll out of the RTS,S (Mosquirix) and R21 (Matrix-M) vaccines”. Instead of being on track to meet the Sustainable Development Goal target of reducing malaria cases by 90% by 2030, global incidence has risen by 8.5%, according to the WHO’s World Health Statistics 2026. Millions of lives at risk In mid-2025, the WHO warned that funding cuts to malaria programmes put “millions of additional lives at risk and could reverse decades of progress”. Between 2010 and 2023, the US contributed around 37% of global malaria financing. By early April 2025, more than 40% of planned distribution of insecticide-treated nets (ITNs) – the cornerstone of malaria prevention – were delayed, according to data provided by national malaria programmes. “Nearly 30% of seasonal malaria chemoprevention (SMC) campaigns to protect 58 million children were also off track,” the WHO reported. Angola told the WHA that malaria is one of its leading causes of morbidity and mortality, yet its efforts to address the disease were being hampered by “climate-related vulnerabilities and declining external financing”. Several other countries mentioned changing climate was increasing their vulnerability to malaria. On a positive note, Cabo Verde became the first sub-Saharan country in 50 years to be certified malaria-free. Suriname, which used to have the highest annual malaria incidence in the Amazon region, has also received the WHO malaria elimination certification. Suriname said its success relied on two critical pillars: decentralised primary health care and the rollout of rapid diagnostic tests and artemisinin-based combination therapy. Malaysia, which aims to be malaria-free by 2030, asked for more WHO support. New plan for tuberculosis The assembly endorsed a decision requesting the Director-General to develop a post-2030 tuberculosis (TB) strategy for the 2028 WHA. Poland reminded the assembly that tuberculosis remains “one of the world’s deadliest infectious diseases, despite being preventable and curable”. Its own TB response had been challenged by “the influx of refugees from Ukraine after 2022”, which it addressed by “flexible, patient-centred, and community-based care”. Poland’s contribution to the post 2030 TB strategy has been focused on drug-resistant TB, migration-sensitive approaches, patient-centred care, and health system resilience. “On tuberculosis, our region is outpacing the world. Incidence is down 28% and mortality down 46% since 2015, and we lead globally on TB-HIV integration,” said Nigeria. Nigeria also noted that 23 African countries have eliminated at least one neglected tropical disease, while vaccination had averted 1.9 million deaths in 2024. “These gains share the same ingredients: political leadership, integrated systems, mobilised communities, and partners align behind one national plan, but they are fragile. “Our region still carries 95% of the global malaria burden. Ten countries account for 80% of zero-dose children. We hold 17% of the world’s 30 high-burden TB countries. “Our frameworks are sound. What is missing is the financing, the integration and the accountability to match them.” World Health Assembly Condemns Iranian Strikes on Gulf States, Health Fallout of Hormuz Closure 21/05/2026 Stefan Anderson The 79th World Health Assembly in session. GENEVA – The World Health Assembly (WHA) voted 91-2 to adopt a resolution condemning Iranian attacks on civilian infrastructure across Gulf countries amid its war with the United States and Israel. The resolution condemns “in the strongest terms” the Iranian attacks on civilians and civilian objects in Gulf states and Jordan, citing damage to “medical and healthcare facilities, water desalination plants, energy facilities, airports and ports.” It further calls on member states to safeguard health system continuity and address disruptions to maritime routes, “including through the Strait of Hormuz, in order to safeguard global health supply chains.” Support for the resolution, spearheaded by the states of the Gulf Cooperation Council (GCC) and Jordan, included every country in the Middle East excluding Iran, all European Union Members, and Ukraine, which has rallied alongside Gulf states due to Iran’s role in supplying drones used by Russia to invade its skies. “These public health consequences addressed in this resolution clearly fall within the mandate of the WHO, and it focuses exclusively on the public health consequences and humanitarian locations resulting from their terrorist Iranian attacks,” the United Arab Emirates said following the vote. Iran was joined only by Nicaragua in opposition. WHA79 voting on the resolution on Iran’s attacks on the Gulf states. “These attacks also have health implications at the global level,” the UAE added. “As we’ve seen from Iran’s disruption of the Strait of Hormuz, and to the essential lifelines for the delivery of medicines, vaccines, medical products, essential health commodities, food, and fuel, all of which are necessary for the functioning of health systems.” The Iranian delegation described the resolution as applying “a selective use of international law”, which it called “inconsistent with the technical, evidence-based and impartial character of this organisation” and setting “a dangerous precedent that risks eroding the main objective and functions” of the WHO. “The proposed text deliberately ignores severe damages inflicted on Iran’s own health infrastructure as a result of military actions in the region,” its delegate said. “It fails to acknowledge the root causes of the current situation, including provocations and aggressions that compel defensive responses while presenting a distorted and incomplete picture of events.” The resolution asks WHO Director-General Dr Tedros Adhanom Ghebreyesus to deliver two reports to next year’s WHA: a global assessment of how Hormuz disruptions and rising energy and transport costs are affecting access to medicines, vaccines and essential health commodities in low- and middle-income countries, and a separate report on the mental health toll of the Iranian attacks and on supply-chain delays for humanitarian medical deliveries. “We are deeply concerned by the suffering of civilians and the destruction of health systems, civilian infrastructure, and supply chains,” Indonesia’s delegation said. “The destruction is profound, but it has not fallen equally across the region. A credible public health response is possible only when all parties cease hostilities and return to the path of diplomacy.” Notable abstentions Thirty-one countries abstained, including Switzerland, Mexico, Russia, South Africa, Brazil, China, Indonesia and Malaysia. China described the Iranian crisis as “one of the most urgent challenges” faced by the international community – and became the only country in the assembly to address the US-sized elephant in the room. “The root cause of this crisis is that an individual country, without the Security Council’s authorisation, has flagrantly launched a military attack on Iran, which seriously violates the basic norms governing international relations based on the principles of the UN charter,” China said. “WHO’s response should follow the principles of objectivity, neutrality, and professionalism, which will help de-escalate the situation rather than aggravating tensions.” South Africa, acknowledging the severe threat of rising energy, fertilizer and seed costs on the livelihoods of people on the African continent in particular, struck a similar middle-ground, noting that while there can be “no military solution” to the war, its “root causes cannot be ignored.” “We have spoken out against attacks on all sides of the conflict. The ravages of the conflict across the region must be acknowledged, as we cannot afford to create a hierarchy of victims,” said South Africa. Strait of Hormuz supply shocks The resolution takes particular aim at the continued de facto closure of the Strait of Hormuz, which has seriously disrupted supply chains for life-saving medicines, food, fertiliser, fuel and commodities on which health systems and the livelihoods of civilian populations depend. “The continued closure of the Strait of Hormuz remains a critical pressure point, disrupting global supply chains and increasing the cost of essential medical commodities,” said WHO Assistant Director-General Dr Chikwe Ihekweazu. “Humanitarian settings are already experiencing funding shortages, now further compounded by fuel, food, and medicine costs.” Several countries in the midst of intense conflicts worsened by the closure of the Strait, including Sudan, Somalia and Yemen, joined the resolution as co-authors. None of the three currently holds voting powers at the WHO due to unpaid membership dues. “The de facto closure of the Strait of Hormuz has only compounded the impacts on already devastated healthcare systems in some of the most vulnerable humanitarian contexts in the world, from Sudan to Gaza,” the UK delegation said. “The delayed supply of medicines and vaccines, and the increasing fuel costs, are reducing the reliability of essential services.” Both the US and Iran blame the closure on one another. Iran has turned the Strait into a minefield and begun enforcing a tiered system of checkpoints and fees, and the US military continues to enforce a blockade on vessels bound for Iran. Countries on both sides of the resolution vote reaffirmed the importance of opening the Strait. Healthcare is a war target now The resolution’s focus on the security of medical personnel and facilities reflects growing concern about the dark tide of violence against health workers and facilities that has come to define modern conflicts. “It cannot be emphasised enough that civilian healthcare personnel, hospitals, and medical facilities must be respected and protected at all times in accordance with international humanitarian law,” Malaysia’s delegate said. Attacks on hospitals, once cause for severe international reckoning and condemnation, are now routine in wars around the globe. Healthcare – in current wars – is now a target. Russian strikes on Ukrainian healthcare since the start of its full-scale invasion surpassed the 3,000 mark earlier this month. In Gaza, WHO has confirmed 2,148 attacks on healthcare since the war began, resulting in 1,048 deaths – destruction so complete UN Special Rapporteurs call it a “medicide”. Amid Sudan’s brutal civil war, the violence inflicted on medical facilities and personnel – particularly in the throws the ongoing genocide in Darfur – is equally extreme, with WHO confirming at least 2,052 deaths. No healthcare strikes While Iran has launched hundreds of missile and drone strikes throughout the region – hitting residential buildings, desalination plants, energy infrastructure, hotels, airports, embassies and other civilian targets, resulting in 41 deaths – no direct attacks on healthcare against Gulf States or Jordan have been documented in the WHO’s Surveillance System for Attacks on Healthcare (SSA) database. Independent global verification authorities, including conflict monitor ACLED and Human Rights Watch, equally list no attacks on healthcare in Gulf countries by Iran’s strikes, out of 660 listed. Israeli health facilities have been hit nine times by Iranian attacks. No deaths or injuries occurred as a result of those strikes, according to WHO data. However, Iranian strikes have repeatedly hit desalination plants, the foundation of clean water systems in the Gulf. Another attack set a fire outside the UAE’s largest nuclear power plant, raising fears it could be targeted again. “Several Gulf countries rely on desalination for 70 to 90% of safe water supplies, making these systems both essential and highly vulnerable,” said Dr Hanan Balky, WHO’s Eastern Mediterranean regional director. “Damage to energy and desalination infrastructure carry major public health risks, including worsening air pollution, disruption to safe water supply and sanitation, and reduced continuity of essential health services.” Resolution from Iran defeated On Tuesday, Lebanon received overwhelming support from the majority of member states in the wake of Israeli attacks on its health infrastructure. Ninety-five member states voted in favour of a resolution that noted “a health emergency in Lebanon resulting from ongoing and recently intensified hostilities” and called for “the full protection of healthcare in Lebanon, including patients, health personnel, facilities and transport”. Only Israel and Honduras opposed the resolution, which did not name Israel as the aggressor. SSA documents 170 attacks on health infrastructure in Lebanon, resulting in 116 deaths of medical personnel and patients. Israeli strikes so far have killed around 2,700 people. “Millions of people have been displaced, approximately 3.2 million internally displaced people in the Islamic Republic, and one million in Lebanon,” Ihekweazu said, citing IOM figures. Meanwhile, the SSA has confirmed 32 attacks on Iranian health facilities since the onset of the violence, resulting in 12 deaths. The US and Israel have launched thousands of bombs across the country, killing a total of at least 3,375 people. However, during the same debate on Tuesday, Iran’s resolution, condemning recent attacks on its patients and health infrastructure, including on the Pasteur Institute, was defeated. Only 19 countries supported Iran, 30 voted against, and a whopping 58 countries abstained. Several countries cited Iran’s attacks against its own citizens and Gulf states, and the blockade of the Strait of Hormuz, preventing the flow of medical supplies, as reasons for not supporting the resolution. Image Credits: X/WHO. EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Polio Eradication Needs Political Commitment as Conflict Makes Vaccination ‘Impossible’ in Areas Like North Yemen 21/05/2026 Disha Shetty Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. The world is in the last stretch of polio eradication, but closing this gap will require political commitment, the World Health Organization (WHO) told member states at the ongoing 79th session of the World Health Assembly (WHA). Polio virus has shown resurgence in conflict-hit or hard-to-reach areas like northern Yemen, Gaza, Afghanistan, and Pakistan. Conflict has limited access in some of these areas and made vaccination campaigns near impossible in others. “We are closer to polio eradication than ever, but the final stretch demands exceptional operational discipline and sustained political commitment. The remaining reservoirs are the hardest to access, the most politically complex, and the most unforgiving of operational gaps,” said Dr Hanan Balkhy, WHO regional director for the Eastern Mediterranean Regional Office (EMRO). WHO said that the support of every member country and the collective political will have brought the world to the brink of success. “The gaps mostly are in the political web, gaps in vaccination coverage, where children are still being missed, gaps in access, where insecurity and instability limit our reach, and gaps in financing, where resources must match the urgency of the final push,” said Dr Razia Pendse, WHO Chef de Cabinet. Wild polio transmission is declining Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean Regional Office (EMRO). Even in areas where the polio cases are endemic, there are showing positive signs of decline. Afghanistan and Pakistan reported 99 wild polio cases in 2024, 52 in 2025 and just six as of May 2026. “Transmission is now limited to a small number of high-risk areas, particularly along cross border corridors between the two countries,” Balkhy said. While the two countries are coordinating for vaccination campaigns, there are still children going without vaccinations in the southern Khyber Pakhtunkhwa region of Pakistan. WHO said it has managed to vaccinate nearly 600,000 children in Gaza, averting a larger polio outbreak. Egypt too managed to successfully interrupt the transmission of the virus with vaccination campaigns which WHO highlighted as an example of a successful result when the political will exists. Northern Yemen is completely out of reach WHO has been unable to conduct vaccination campaigns in conflict-hit northern Yemen. In northern Yemen, an outbreak has paralysed 450 children. “Most of them in the northern governance, where no mass vaccination campaign has been possible since 2022, and we continue to try. I urge member states to continue raising the need for access as a priority in northern Yemen,” Balkhy said. Yemen had been polio-free since the year 2006. Balkhy assured that the WHO is pushing for improved access for polio eradication campaigns, and asked others to do so as well. Canada highlighted the important role of the health workers against such a harsh backdrop. “The tireless efforts of frontline health workers, the majority of whom were women, made this achievement possible. We want to highlight the challenging context in which these health workers perform their duty every day, in some cases at risk to their personal safety,” Canada’s representative told WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Access and funding challenges The 79th World Health Assembly in session. Unpredictable funding is getting in the way of the polio eradication campaign. The campaigns have been plagued by funding challenges, and the gap is a whopping $2.3 billion. “Several countries, including Iraq, Libya, and Syria have already transitioned polio functions to domestic financing, demonstrating that polio infrastructure, when embedded in health systems, delivers lasting returns,” Balkhy said, citing examples of countries that have become self-reliant. The global vaccine alliance, Gavi, has urged countries to use an integrated approach to reach zero-dose children with vaccination and primary health care, especially in humanitarian settings and emergencies. It assured countries of its continued support. It is an approach that Japan too supported, adding that the country, “will continue to work in collaboration with WHO and other relevant organizations to contribute to polio eradication and to sustaining a polio-free world beyond eradication.” “To finally end polio, we must sustain access, close funding gaps, maintain operational discipline, and reach every last child. If we do that, and I’m pretty sure we will finish this job,” Balkhy said. Image Credits: WHO, WHO Yemen, X/WHO. Restore Funds for Malaria, Africa Urges 21/05/2026 Kerry Cullinan Nigeria, on behalf of African states, called for more investment in malaria. The African region made an impassioned appeal for global funding to be restored for malaria elimination at the World Health Assembly on Wednesday. Drastic aid cuts in the past 18 months, particularly by the United States, have had a dramatic effect on malaria efforts – particularly as they coincide with growing drug resistance. Nigeria, speaking for African member states, noted that the World Health Organization’s (WHO) malaria elimination effort known as E-2025 has not been funded since 2024. The initiative had focused on supporting 25 countries with the potential to eliminate malaria by 2025 with Global Fund money. Around 95% of global malaria cases are in Africa, and Nigeria is the worst-affected country in the world, accounting for almost a quarter of the world’s malaria cases and a third of all deaths. It requested the assembly to “restore financing for malaria elimination, including the E 2025 initiative, and accelerate roll out of the RTS,S (Mosquirix) and R21 (Matrix-M) vaccines”. Instead of being on track to meet the Sustainable Development Goal target of reducing malaria cases by 90% by 2030, global incidence has risen by 8.5%, according to the WHO’s World Health Statistics 2026. Millions of lives at risk In mid-2025, the WHO warned that funding cuts to malaria programmes put “millions of additional lives at risk and could reverse decades of progress”. Between 2010 and 2023, the US contributed around 37% of global malaria financing. By early April 2025, more than 40% of planned distribution of insecticide-treated nets (ITNs) – the cornerstone of malaria prevention – were delayed, according to data provided by national malaria programmes. “Nearly 30% of seasonal malaria chemoprevention (SMC) campaigns to protect 58 million children were also off track,” the WHO reported. Angola told the WHA that malaria is one of its leading causes of morbidity and mortality, yet its efforts to address the disease were being hampered by “climate-related vulnerabilities and declining external financing”. Several other countries mentioned changing climate was increasing their vulnerability to malaria. On a positive note, Cabo Verde became the first sub-Saharan country in 50 years to be certified malaria-free. Suriname, which used to have the highest annual malaria incidence in the Amazon region, has also received the WHO malaria elimination certification. Suriname said its success relied on two critical pillars: decentralised primary health care and the rollout of rapid diagnostic tests and artemisinin-based combination therapy. Malaysia, which aims to be malaria-free by 2030, asked for more WHO support. New plan for tuberculosis The assembly endorsed a decision requesting the Director-General to develop a post-2030 tuberculosis (TB) strategy for the 2028 WHA. Poland reminded the assembly that tuberculosis remains “one of the world’s deadliest infectious diseases, despite being preventable and curable”. Its own TB response had been challenged by “the influx of refugees from Ukraine after 2022”, which it addressed by “flexible, patient-centred, and community-based care”. Poland’s contribution to the post 2030 TB strategy has been focused on drug-resistant TB, migration-sensitive approaches, patient-centred care, and health system resilience. “On tuberculosis, our region is outpacing the world. Incidence is down 28% and mortality down 46% since 2015, and we lead globally on TB-HIV integration,” said Nigeria. Nigeria also noted that 23 African countries have eliminated at least one neglected tropical disease, while vaccination had averted 1.9 million deaths in 2024. “These gains share the same ingredients: political leadership, integrated systems, mobilised communities, and partners align behind one national plan, but they are fragile. “Our region still carries 95% of the global malaria burden. Ten countries account for 80% of zero-dose children. We hold 17% of the world’s 30 high-burden TB countries. “Our frameworks are sound. What is missing is the financing, the integration and the accountability to match them.” World Health Assembly Condemns Iranian Strikes on Gulf States, Health Fallout of Hormuz Closure 21/05/2026 Stefan Anderson The 79th World Health Assembly in session. GENEVA – The World Health Assembly (WHA) voted 91-2 to adopt a resolution condemning Iranian attacks on civilian infrastructure across Gulf countries amid its war with the United States and Israel. The resolution condemns “in the strongest terms” the Iranian attacks on civilians and civilian objects in Gulf states and Jordan, citing damage to “medical and healthcare facilities, water desalination plants, energy facilities, airports and ports.” It further calls on member states to safeguard health system continuity and address disruptions to maritime routes, “including through the Strait of Hormuz, in order to safeguard global health supply chains.” Support for the resolution, spearheaded by the states of the Gulf Cooperation Council (GCC) and Jordan, included every country in the Middle East excluding Iran, all European Union Members, and Ukraine, which has rallied alongside Gulf states due to Iran’s role in supplying drones used by Russia to invade its skies. “These public health consequences addressed in this resolution clearly fall within the mandate of the WHO, and it focuses exclusively on the public health consequences and humanitarian locations resulting from their terrorist Iranian attacks,” the United Arab Emirates said following the vote. Iran was joined only by Nicaragua in opposition. WHA79 voting on the resolution on Iran’s attacks on the Gulf states. “These attacks also have health implications at the global level,” the UAE added. “As we’ve seen from Iran’s disruption of the Strait of Hormuz, and to the essential lifelines for the delivery of medicines, vaccines, medical products, essential health commodities, food, and fuel, all of which are necessary for the functioning of health systems.” The Iranian delegation described the resolution as applying “a selective use of international law”, which it called “inconsistent with the technical, evidence-based and impartial character of this organisation” and setting “a dangerous precedent that risks eroding the main objective and functions” of the WHO. “The proposed text deliberately ignores severe damages inflicted on Iran’s own health infrastructure as a result of military actions in the region,” its delegate said. “It fails to acknowledge the root causes of the current situation, including provocations and aggressions that compel defensive responses while presenting a distorted and incomplete picture of events.” The resolution asks WHO Director-General Dr Tedros Adhanom Ghebreyesus to deliver two reports to next year’s WHA: a global assessment of how Hormuz disruptions and rising energy and transport costs are affecting access to medicines, vaccines and essential health commodities in low- and middle-income countries, and a separate report on the mental health toll of the Iranian attacks and on supply-chain delays for humanitarian medical deliveries. “We are deeply concerned by the suffering of civilians and the destruction of health systems, civilian infrastructure, and supply chains,” Indonesia’s delegation said. “The destruction is profound, but it has not fallen equally across the region. A credible public health response is possible only when all parties cease hostilities and return to the path of diplomacy.” Notable abstentions Thirty-one countries abstained, including Switzerland, Mexico, Russia, South Africa, Brazil, China, Indonesia and Malaysia. China described the Iranian crisis as “one of the most urgent challenges” faced by the international community – and became the only country in the assembly to address the US-sized elephant in the room. “The root cause of this crisis is that an individual country, without the Security Council’s authorisation, has flagrantly launched a military attack on Iran, which seriously violates the basic norms governing international relations based on the principles of the UN charter,” China said. “WHO’s response should follow the principles of objectivity, neutrality, and professionalism, which will help de-escalate the situation rather than aggravating tensions.” South Africa, acknowledging the severe threat of rising energy, fertilizer and seed costs on the livelihoods of people on the African continent in particular, struck a similar middle-ground, noting that while there can be “no military solution” to the war, its “root causes cannot be ignored.” “We have spoken out against attacks on all sides of the conflict. The ravages of the conflict across the region must be acknowledged, as we cannot afford to create a hierarchy of victims,” said South Africa. Strait of Hormuz supply shocks The resolution takes particular aim at the continued de facto closure of the Strait of Hormuz, which has seriously disrupted supply chains for life-saving medicines, food, fertiliser, fuel and commodities on which health systems and the livelihoods of civilian populations depend. “The continued closure of the Strait of Hormuz remains a critical pressure point, disrupting global supply chains and increasing the cost of essential medical commodities,” said WHO Assistant Director-General Dr Chikwe Ihekweazu. “Humanitarian settings are already experiencing funding shortages, now further compounded by fuel, food, and medicine costs.” Several countries in the midst of intense conflicts worsened by the closure of the Strait, including Sudan, Somalia and Yemen, joined the resolution as co-authors. None of the three currently holds voting powers at the WHO due to unpaid membership dues. “The de facto closure of the Strait of Hormuz has only compounded the impacts on already devastated healthcare systems in some of the most vulnerable humanitarian contexts in the world, from Sudan to Gaza,” the UK delegation said. “The delayed supply of medicines and vaccines, and the increasing fuel costs, are reducing the reliability of essential services.” Both the US and Iran blame the closure on one another. Iran has turned the Strait into a minefield and begun enforcing a tiered system of checkpoints and fees, and the US military continues to enforce a blockade on vessels bound for Iran. Countries on both sides of the resolution vote reaffirmed the importance of opening the Strait. Healthcare is a war target now The resolution’s focus on the security of medical personnel and facilities reflects growing concern about the dark tide of violence against health workers and facilities that has come to define modern conflicts. “It cannot be emphasised enough that civilian healthcare personnel, hospitals, and medical facilities must be respected and protected at all times in accordance with international humanitarian law,” Malaysia’s delegate said. Attacks on hospitals, once cause for severe international reckoning and condemnation, are now routine in wars around the globe. Healthcare – in current wars – is now a target. Russian strikes on Ukrainian healthcare since the start of its full-scale invasion surpassed the 3,000 mark earlier this month. In Gaza, WHO has confirmed 2,148 attacks on healthcare since the war began, resulting in 1,048 deaths – destruction so complete UN Special Rapporteurs call it a “medicide”. Amid Sudan’s brutal civil war, the violence inflicted on medical facilities and personnel – particularly in the throws the ongoing genocide in Darfur – is equally extreme, with WHO confirming at least 2,052 deaths. No healthcare strikes While Iran has launched hundreds of missile and drone strikes throughout the region – hitting residential buildings, desalination plants, energy infrastructure, hotels, airports, embassies and other civilian targets, resulting in 41 deaths – no direct attacks on healthcare against Gulf States or Jordan have been documented in the WHO’s Surveillance System for Attacks on Healthcare (SSA) database. Independent global verification authorities, including conflict monitor ACLED and Human Rights Watch, equally list no attacks on healthcare in Gulf countries by Iran’s strikes, out of 660 listed. Israeli health facilities have been hit nine times by Iranian attacks. No deaths or injuries occurred as a result of those strikes, according to WHO data. However, Iranian strikes have repeatedly hit desalination plants, the foundation of clean water systems in the Gulf. Another attack set a fire outside the UAE’s largest nuclear power plant, raising fears it could be targeted again. “Several Gulf countries rely on desalination for 70 to 90% of safe water supplies, making these systems both essential and highly vulnerable,” said Dr Hanan Balky, WHO’s Eastern Mediterranean regional director. “Damage to energy and desalination infrastructure carry major public health risks, including worsening air pollution, disruption to safe water supply and sanitation, and reduced continuity of essential health services.” Resolution from Iran defeated On Tuesday, Lebanon received overwhelming support from the majority of member states in the wake of Israeli attacks on its health infrastructure. Ninety-five member states voted in favour of a resolution that noted “a health emergency in Lebanon resulting from ongoing and recently intensified hostilities” and called for “the full protection of healthcare in Lebanon, including patients, health personnel, facilities and transport”. Only Israel and Honduras opposed the resolution, which did not name Israel as the aggressor. SSA documents 170 attacks on health infrastructure in Lebanon, resulting in 116 deaths of medical personnel and patients. Israeli strikes so far have killed around 2,700 people. “Millions of people have been displaced, approximately 3.2 million internally displaced people in the Islamic Republic, and one million in Lebanon,” Ihekweazu said, citing IOM figures. Meanwhile, the SSA has confirmed 32 attacks on Iranian health facilities since the onset of the violence, resulting in 12 deaths. The US and Israel have launched thousands of bombs across the country, killing a total of at least 3,375 people. However, during the same debate on Tuesday, Iran’s resolution, condemning recent attacks on its patients and health infrastructure, including on the Pasteur Institute, was defeated. Only 19 countries supported Iran, 30 voted against, and a whopping 58 countries abstained. Several countries cited Iran’s attacks against its own citizens and Gulf states, and the blockade of the Strait of Hormuz, preventing the flow of medical supplies, as reasons for not supporting the resolution. Image Credits: X/WHO. EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Restore Funds for Malaria, Africa Urges 21/05/2026 Kerry Cullinan Nigeria, on behalf of African states, called for more investment in malaria. The African region made an impassioned appeal for global funding to be restored for malaria elimination at the World Health Assembly on Wednesday. Drastic aid cuts in the past 18 months, particularly by the United States, have had a dramatic effect on malaria efforts – particularly as they coincide with growing drug resistance. Nigeria, speaking for African member states, noted that the World Health Organization’s (WHO) malaria elimination effort known as E-2025 has not been funded since 2024. The initiative had focused on supporting 25 countries with the potential to eliminate malaria by 2025 with Global Fund money. Around 95% of global malaria cases are in Africa, and Nigeria is the worst-affected country in the world, accounting for almost a quarter of the world’s malaria cases and a third of all deaths. It requested the assembly to “restore financing for malaria elimination, including the E 2025 initiative, and accelerate roll out of the RTS,S (Mosquirix) and R21 (Matrix-M) vaccines”. Instead of being on track to meet the Sustainable Development Goal target of reducing malaria cases by 90% by 2030, global incidence has risen by 8.5%, according to the WHO’s World Health Statistics 2026. Millions of lives at risk In mid-2025, the WHO warned that funding cuts to malaria programmes put “millions of additional lives at risk and could reverse decades of progress”. Between 2010 and 2023, the US contributed around 37% of global malaria financing. By early April 2025, more than 40% of planned distribution of insecticide-treated nets (ITNs) – the cornerstone of malaria prevention – were delayed, according to data provided by national malaria programmes. “Nearly 30% of seasonal malaria chemoprevention (SMC) campaigns to protect 58 million children were also off track,” the WHO reported. Angola told the WHA that malaria is one of its leading causes of morbidity and mortality, yet its efforts to address the disease were being hampered by “climate-related vulnerabilities and declining external financing”. Several other countries mentioned changing climate was increasing their vulnerability to malaria. On a positive note, Cabo Verde became the first sub-Saharan country in 50 years to be certified malaria-free. Suriname, which used to have the highest annual malaria incidence in the Amazon region, has also received the WHO malaria elimination certification. Suriname said its success relied on two critical pillars: decentralised primary health care and the rollout of rapid diagnostic tests and artemisinin-based combination therapy. Malaysia, which aims to be malaria-free by 2030, asked for more WHO support. New plan for tuberculosis The assembly endorsed a decision requesting the Director-General to develop a post-2030 tuberculosis (TB) strategy for the 2028 WHA. Poland reminded the assembly that tuberculosis remains “one of the world’s deadliest infectious diseases, despite being preventable and curable”. Its own TB response had been challenged by “the influx of refugees from Ukraine after 2022”, which it addressed by “flexible, patient-centred, and community-based care”. Poland’s contribution to the post 2030 TB strategy has been focused on drug-resistant TB, migration-sensitive approaches, patient-centred care, and health system resilience. “On tuberculosis, our region is outpacing the world. Incidence is down 28% and mortality down 46% since 2015, and we lead globally on TB-HIV integration,” said Nigeria. Nigeria also noted that 23 African countries have eliminated at least one neglected tropical disease, while vaccination had averted 1.9 million deaths in 2024. “These gains share the same ingredients: political leadership, integrated systems, mobilised communities, and partners align behind one national plan, but they are fragile. “Our region still carries 95% of the global malaria burden. Ten countries account for 80% of zero-dose children. We hold 17% of the world’s 30 high-burden TB countries. “Our frameworks are sound. What is missing is the financing, the integration and the accountability to match them.” World Health Assembly Condemns Iranian Strikes on Gulf States, Health Fallout of Hormuz Closure 21/05/2026 Stefan Anderson The 79th World Health Assembly in session. GENEVA – The World Health Assembly (WHA) voted 91-2 to adopt a resolution condemning Iranian attacks on civilian infrastructure across Gulf countries amid its war with the United States and Israel. The resolution condemns “in the strongest terms” the Iranian attacks on civilians and civilian objects in Gulf states and Jordan, citing damage to “medical and healthcare facilities, water desalination plants, energy facilities, airports and ports.” It further calls on member states to safeguard health system continuity and address disruptions to maritime routes, “including through the Strait of Hormuz, in order to safeguard global health supply chains.” Support for the resolution, spearheaded by the states of the Gulf Cooperation Council (GCC) and Jordan, included every country in the Middle East excluding Iran, all European Union Members, and Ukraine, which has rallied alongside Gulf states due to Iran’s role in supplying drones used by Russia to invade its skies. “These public health consequences addressed in this resolution clearly fall within the mandate of the WHO, and it focuses exclusively on the public health consequences and humanitarian locations resulting from their terrorist Iranian attacks,” the United Arab Emirates said following the vote. Iran was joined only by Nicaragua in opposition. WHA79 voting on the resolution on Iran’s attacks on the Gulf states. “These attacks also have health implications at the global level,” the UAE added. “As we’ve seen from Iran’s disruption of the Strait of Hormuz, and to the essential lifelines for the delivery of medicines, vaccines, medical products, essential health commodities, food, and fuel, all of which are necessary for the functioning of health systems.” The Iranian delegation described the resolution as applying “a selective use of international law”, which it called “inconsistent with the technical, evidence-based and impartial character of this organisation” and setting “a dangerous precedent that risks eroding the main objective and functions” of the WHO. “The proposed text deliberately ignores severe damages inflicted on Iran’s own health infrastructure as a result of military actions in the region,” its delegate said. “It fails to acknowledge the root causes of the current situation, including provocations and aggressions that compel defensive responses while presenting a distorted and incomplete picture of events.” The resolution asks WHO Director-General Dr Tedros Adhanom Ghebreyesus to deliver two reports to next year’s WHA: a global assessment of how Hormuz disruptions and rising energy and transport costs are affecting access to medicines, vaccines and essential health commodities in low- and middle-income countries, and a separate report on the mental health toll of the Iranian attacks and on supply-chain delays for humanitarian medical deliveries. “We are deeply concerned by the suffering of civilians and the destruction of health systems, civilian infrastructure, and supply chains,” Indonesia’s delegation said. “The destruction is profound, but it has not fallen equally across the region. A credible public health response is possible only when all parties cease hostilities and return to the path of diplomacy.” Notable abstentions Thirty-one countries abstained, including Switzerland, Mexico, Russia, South Africa, Brazil, China, Indonesia and Malaysia. China described the Iranian crisis as “one of the most urgent challenges” faced by the international community – and became the only country in the assembly to address the US-sized elephant in the room. “The root cause of this crisis is that an individual country, without the Security Council’s authorisation, has flagrantly launched a military attack on Iran, which seriously violates the basic norms governing international relations based on the principles of the UN charter,” China said. “WHO’s response should follow the principles of objectivity, neutrality, and professionalism, which will help de-escalate the situation rather than aggravating tensions.” South Africa, acknowledging the severe threat of rising energy, fertilizer and seed costs on the livelihoods of people on the African continent in particular, struck a similar middle-ground, noting that while there can be “no military solution” to the war, its “root causes cannot be ignored.” “We have spoken out against attacks on all sides of the conflict. The ravages of the conflict across the region must be acknowledged, as we cannot afford to create a hierarchy of victims,” said South Africa. Strait of Hormuz supply shocks The resolution takes particular aim at the continued de facto closure of the Strait of Hormuz, which has seriously disrupted supply chains for life-saving medicines, food, fertiliser, fuel and commodities on which health systems and the livelihoods of civilian populations depend. “The continued closure of the Strait of Hormuz remains a critical pressure point, disrupting global supply chains and increasing the cost of essential medical commodities,” said WHO Assistant Director-General Dr Chikwe Ihekweazu. “Humanitarian settings are already experiencing funding shortages, now further compounded by fuel, food, and medicine costs.” Several countries in the midst of intense conflicts worsened by the closure of the Strait, including Sudan, Somalia and Yemen, joined the resolution as co-authors. None of the three currently holds voting powers at the WHO due to unpaid membership dues. “The de facto closure of the Strait of Hormuz has only compounded the impacts on already devastated healthcare systems in some of the most vulnerable humanitarian contexts in the world, from Sudan to Gaza,” the UK delegation said. “The delayed supply of medicines and vaccines, and the increasing fuel costs, are reducing the reliability of essential services.” Both the US and Iran blame the closure on one another. Iran has turned the Strait into a minefield and begun enforcing a tiered system of checkpoints and fees, and the US military continues to enforce a blockade on vessels bound for Iran. Countries on both sides of the resolution vote reaffirmed the importance of opening the Strait. Healthcare is a war target now The resolution’s focus on the security of medical personnel and facilities reflects growing concern about the dark tide of violence against health workers and facilities that has come to define modern conflicts. “It cannot be emphasised enough that civilian healthcare personnel, hospitals, and medical facilities must be respected and protected at all times in accordance with international humanitarian law,” Malaysia’s delegate said. Attacks on hospitals, once cause for severe international reckoning and condemnation, are now routine in wars around the globe. Healthcare – in current wars – is now a target. Russian strikes on Ukrainian healthcare since the start of its full-scale invasion surpassed the 3,000 mark earlier this month. In Gaza, WHO has confirmed 2,148 attacks on healthcare since the war began, resulting in 1,048 deaths – destruction so complete UN Special Rapporteurs call it a “medicide”. Amid Sudan’s brutal civil war, the violence inflicted on medical facilities and personnel – particularly in the throws the ongoing genocide in Darfur – is equally extreme, with WHO confirming at least 2,052 deaths. No healthcare strikes While Iran has launched hundreds of missile and drone strikes throughout the region – hitting residential buildings, desalination plants, energy infrastructure, hotels, airports, embassies and other civilian targets, resulting in 41 deaths – no direct attacks on healthcare against Gulf States or Jordan have been documented in the WHO’s Surveillance System for Attacks on Healthcare (SSA) database. Independent global verification authorities, including conflict monitor ACLED and Human Rights Watch, equally list no attacks on healthcare in Gulf countries by Iran’s strikes, out of 660 listed. Israeli health facilities have been hit nine times by Iranian attacks. No deaths or injuries occurred as a result of those strikes, according to WHO data. However, Iranian strikes have repeatedly hit desalination plants, the foundation of clean water systems in the Gulf. Another attack set a fire outside the UAE’s largest nuclear power plant, raising fears it could be targeted again. “Several Gulf countries rely on desalination for 70 to 90% of safe water supplies, making these systems both essential and highly vulnerable,” said Dr Hanan Balky, WHO’s Eastern Mediterranean regional director. “Damage to energy and desalination infrastructure carry major public health risks, including worsening air pollution, disruption to safe water supply and sanitation, and reduced continuity of essential health services.” Resolution from Iran defeated On Tuesday, Lebanon received overwhelming support from the majority of member states in the wake of Israeli attacks on its health infrastructure. Ninety-five member states voted in favour of a resolution that noted “a health emergency in Lebanon resulting from ongoing and recently intensified hostilities” and called for “the full protection of healthcare in Lebanon, including patients, health personnel, facilities and transport”. Only Israel and Honduras opposed the resolution, which did not name Israel as the aggressor. SSA documents 170 attacks on health infrastructure in Lebanon, resulting in 116 deaths of medical personnel and patients. Israeli strikes so far have killed around 2,700 people. “Millions of people have been displaced, approximately 3.2 million internally displaced people in the Islamic Republic, and one million in Lebanon,” Ihekweazu said, citing IOM figures. Meanwhile, the SSA has confirmed 32 attacks on Iranian health facilities since the onset of the violence, resulting in 12 deaths. The US and Israel have launched thousands of bombs across the country, killing a total of at least 3,375 people. However, during the same debate on Tuesday, Iran’s resolution, condemning recent attacks on its patients and health infrastructure, including on the Pasteur Institute, was defeated. Only 19 countries supported Iran, 30 voted against, and a whopping 58 countries abstained. Several countries cited Iran’s attacks against its own citizens and Gulf states, and the blockade of the Strait of Hormuz, preventing the flow of medical supplies, as reasons for not supporting the resolution. Image Credits: X/WHO. EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
World Health Assembly Condemns Iranian Strikes on Gulf States, Health Fallout of Hormuz Closure 21/05/2026 Stefan Anderson The 79th World Health Assembly in session. GENEVA – The World Health Assembly (WHA) voted 91-2 to adopt a resolution condemning Iranian attacks on civilian infrastructure across Gulf countries amid its war with the United States and Israel. The resolution condemns “in the strongest terms” the Iranian attacks on civilians and civilian objects in Gulf states and Jordan, citing damage to “medical and healthcare facilities, water desalination plants, energy facilities, airports and ports.” It further calls on member states to safeguard health system continuity and address disruptions to maritime routes, “including through the Strait of Hormuz, in order to safeguard global health supply chains.” Support for the resolution, spearheaded by the states of the Gulf Cooperation Council (GCC) and Jordan, included every country in the Middle East excluding Iran, all European Union Members, and Ukraine, which has rallied alongside Gulf states due to Iran’s role in supplying drones used by Russia to invade its skies. “These public health consequences addressed in this resolution clearly fall within the mandate of the WHO, and it focuses exclusively on the public health consequences and humanitarian locations resulting from their terrorist Iranian attacks,” the United Arab Emirates said following the vote. Iran was joined only by Nicaragua in opposition. WHA79 voting on the resolution on Iran’s attacks on the Gulf states. “These attacks also have health implications at the global level,” the UAE added. “As we’ve seen from Iran’s disruption of the Strait of Hormuz, and to the essential lifelines for the delivery of medicines, vaccines, medical products, essential health commodities, food, and fuel, all of which are necessary for the functioning of health systems.” The Iranian delegation described the resolution as applying “a selective use of international law”, which it called “inconsistent with the technical, evidence-based and impartial character of this organisation” and setting “a dangerous precedent that risks eroding the main objective and functions” of the WHO. “The proposed text deliberately ignores severe damages inflicted on Iran’s own health infrastructure as a result of military actions in the region,” its delegate said. “It fails to acknowledge the root causes of the current situation, including provocations and aggressions that compel defensive responses while presenting a distorted and incomplete picture of events.” The resolution asks WHO Director-General Dr Tedros Adhanom Ghebreyesus to deliver two reports to next year’s WHA: a global assessment of how Hormuz disruptions and rising energy and transport costs are affecting access to medicines, vaccines and essential health commodities in low- and middle-income countries, and a separate report on the mental health toll of the Iranian attacks and on supply-chain delays for humanitarian medical deliveries. “We are deeply concerned by the suffering of civilians and the destruction of health systems, civilian infrastructure, and supply chains,” Indonesia’s delegation said. “The destruction is profound, but it has not fallen equally across the region. A credible public health response is possible only when all parties cease hostilities and return to the path of diplomacy.” Notable abstentions Thirty-one countries abstained, including Switzerland, Mexico, Russia, South Africa, Brazil, China, Indonesia and Malaysia. China described the Iranian crisis as “one of the most urgent challenges” faced by the international community – and became the only country in the assembly to address the US-sized elephant in the room. “The root cause of this crisis is that an individual country, without the Security Council’s authorisation, has flagrantly launched a military attack on Iran, which seriously violates the basic norms governing international relations based on the principles of the UN charter,” China said. “WHO’s response should follow the principles of objectivity, neutrality, and professionalism, which will help de-escalate the situation rather than aggravating tensions.” South Africa, acknowledging the severe threat of rising energy, fertilizer and seed costs on the livelihoods of people on the African continent in particular, struck a similar middle-ground, noting that while there can be “no military solution” to the war, its “root causes cannot be ignored.” “We have spoken out against attacks on all sides of the conflict. The ravages of the conflict across the region must be acknowledged, as we cannot afford to create a hierarchy of victims,” said South Africa. Strait of Hormuz supply shocks The resolution takes particular aim at the continued de facto closure of the Strait of Hormuz, which has seriously disrupted supply chains for life-saving medicines, food, fertiliser, fuel and commodities on which health systems and the livelihoods of civilian populations depend. “The continued closure of the Strait of Hormuz remains a critical pressure point, disrupting global supply chains and increasing the cost of essential medical commodities,” said WHO Assistant Director-General Dr Chikwe Ihekweazu. “Humanitarian settings are already experiencing funding shortages, now further compounded by fuel, food, and medicine costs.” Several countries in the midst of intense conflicts worsened by the closure of the Strait, including Sudan, Somalia and Yemen, joined the resolution as co-authors. None of the three currently holds voting powers at the WHO due to unpaid membership dues. “The de facto closure of the Strait of Hormuz has only compounded the impacts on already devastated healthcare systems in some of the most vulnerable humanitarian contexts in the world, from Sudan to Gaza,” the UK delegation said. “The delayed supply of medicines and vaccines, and the increasing fuel costs, are reducing the reliability of essential services.” Both the US and Iran blame the closure on one another. Iran has turned the Strait into a minefield and begun enforcing a tiered system of checkpoints and fees, and the US military continues to enforce a blockade on vessels bound for Iran. Countries on both sides of the resolution vote reaffirmed the importance of opening the Strait. Healthcare is a war target now The resolution’s focus on the security of medical personnel and facilities reflects growing concern about the dark tide of violence against health workers and facilities that has come to define modern conflicts. “It cannot be emphasised enough that civilian healthcare personnel, hospitals, and medical facilities must be respected and protected at all times in accordance with international humanitarian law,” Malaysia’s delegate said. Attacks on hospitals, once cause for severe international reckoning and condemnation, are now routine in wars around the globe. Healthcare – in current wars – is now a target. Russian strikes on Ukrainian healthcare since the start of its full-scale invasion surpassed the 3,000 mark earlier this month. In Gaza, WHO has confirmed 2,148 attacks on healthcare since the war began, resulting in 1,048 deaths – destruction so complete UN Special Rapporteurs call it a “medicide”. Amid Sudan’s brutal civil war, the violence inflicted on medical facilities and personnel – particularly in the throws the ongoing genocide in Darfur – is equally extreme, with WHO confirming at least 2,052 deaths. No healthcare strikes While Iran has launched hundreds of missile and drone strikes throughout the region – hitting residential buildings, desalination plants, energy infrastructure, hotels, airports, embassies and other civilian targets, resulting in 41 deaths – no direct attacks on healthcare against Gulf States or Jordan have been documented in the WHO’s Surveillance System for Attacks on Healthcare (SSA) database. Independent global verification authorities, including conflict monitor ACLED and Human Rights Watch, equally list no attacks on healthcare in Gulf countries by Iran’s strikes, out of 660 listed. Israeli health facilities have been hit nine times by Iranian attacks. No deaths or injuries occurred as a result of those strikes, according to WHO data. However, Iranian strikes have repeatedly hit desalination plants, the foundation of clean water systems in the Gulf. Another attack set a fire outside the UAE’s largest nuclear power plant, raising fears it could be targeted again. “Several Gulf countries rely on desalination for 70 to 90% of safe water supplies, making these systems both essential and highly vulnerable,” said Dr Hanan Balky, WHO’s Eastern Mediterranean regional director. “Damage to energy and desalination infrastructure carry major public health risks, including worsening air pollution, disruption to safe water supply and sanitation, and reduced continuity of essential health services.” Resolution from Iran defeated On Tuesday, Lebanon received overwhelming support from the majority of member states in the wake of Israeli attacks on its health infrastructure. Ninety-five member states voted in favour of a resolution that noted “a health emergency in Lebanon resulting from ongoing and recently intensified hostilities” and called for “the full protection of healthcare in Lebanon, including patients, health personnel, facilities and transport”. Only Israel and Honduras opposed the resolution, which did not name Israel as the aggressor. SSA documents 170 attacks on health infrastructure in Lebanon, resulting in 116 deaths of medical personnel and patients. Israeli strikes so far have killed around 2,700 people. “Millions of people have been displaced, approximately 3.2 million internally displaced people in the Islamic Republic, and one million in Lebanon,” Ihekweazu said, citing IOM figures. Meanwhile, the SSA has confirmed 32 attacks on Iranian health facilities since the onset of the violence, resulting in 12 deaths. The US and Israel have launched thousands of bombs across the country, killing a total of at least 3,375 people. However, during the same debate on Tuesday, Iran’s resolution, condemning recent attacks on its patients and health infrastructure, including on the Pasteur Institute, was defeated. Only 19 countries supported Iran, 30 voted against, and a whopping 58 countries abstained. Several countries cited Iran’s attacks against its own citizens and Gulf states, and the blockade of the Strait of Hormuz, preventing the flow of medical supplies, as reasons for not supporting the resolution. Image Credits: X/WHO. EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
EXCLUSIVE: World Health Assembly to Suspend USA’s Voting Rights, Retains Iran’s 21/05/2026 Felix Sassmannshausen & Elaine Ruth Fletcher Delegates attend the WHA Committee B meeting in the Assembly Hall at the Palais des Nations on Thursday after the decision to restore Iranian voting rights. WHO member states on Thursday agreed to suspend the voting rights of the United States in the World Health Assembly as of May 2027 if some $280 million in outstanding 2024–25 dues remain unpaid – despite the US announcement of withdrawal last year. In the same resolution, the suspension of Iran’s voting rights was averted after it caught up on outstanding debts. The decision by WHA’s Committee B, which was approved by consensus and without any debate, signals that member states won’t recognize the US announced withdrawal from WHO in 2025 until the back dues are paid, in accordance with a Congressional decision made at the time when the US joined WHO in 1948. Former WHO Legal Counsel, Gian Luca Burci, described the little-noticed technical decision as politically and legally “consequential,” in a comment to Health Policy Watch. “Even with all the unavoidable ambiguities in such an unusual situation, WHO has not accepted its withdrawal because the US has not fulfilled the terms that they [the US] themselves imposed back in 1948. So, at least on the basis of the advice of the WHO Secretariat to the Executive Board in February, for WHO the US is still a member until it pays its assessed contribution.” The self-declared American exit in January 2025 forced the global health body to reduce its upcoming base budget by 21%, to $4.2 billion, leading to layoffs of nearly 25% of WHO staff in a convulsive year of internal programme cuts and reorganization. According to the WHO Constitution, there is no real provision for member states to withdraw. The sole exception was the US, which made the right to withdraw a condition of joining the global health body in 1948, a stipulation that WHO accepted at the time. However, according to the US’s own rules set by Congress, that right would only be effective if outstanding dues were paid, stating: “The United States reserves its right to withdraw from the organization on a one-year notice, provided, however, that the financial obligations of the United States to the organization shall be met in full for the organization’s current fiscal year.” And, if the following limbo continues, more years of unpaid US dues would technically pile up in 2026 – until the issue is otherwise resolved. WHA to decide on voting rights and Argentina’s exit Tomorrow, the Assembly is also set to address the self-declared departure of Argentina last year in what is likely to lead to a more prolonged debate. Draft decisions currently circulating propose two contradictory paths forward. A proposal put forward by Paraguay would formally “recognize” Argentina’s withdrawal – despite the absence of a legal exit ramp in the WHO constitution. However, a competing draft decision proposed by a separate group of countries, including Germany, takes a decidedly more passive approach. This alternate draft merely “takes note of the request from the UN legal counsel for a WHO clarification on the status of Argentina’s request to withdraw,” Burci explained. This manoeuvre intentionally leaves “the situation ambiguous because the membership is divided on whether Argentina has the right to withdraw, and so effectively the WHA doesn’t take any concrete decision.” If delegates were to adopt Paraguay’s proposal, it would set a significant legal precedent. The WHO Constitution currently contains no provision for a member state to withdraw, and the organization has never formally accepted such a departure in its history. When seven Soviet-bloc nations attempted to withdraw in 1949 and 1950, the organization refused to accept their exit. The WHO instead treated these states as “inactive members”. When the countries sought to resume active participation a few years later, the World Health Assembly allowed them to return by submitting a fraction of their unpaid dues, completely bypassing the need for a formal re-accession process. Looking ahead, the silent committee approval of the American suspension could, nonetheless, provoke more debate – and diplomatic fallout on the issue at Saturday’s final, plenary session. Typically, the decisions of the WHA’s two Committees (A and B) are merely gavelled to approval in rapid succession in the final plenary, with no further debate. But nothing about the US withdrawal from WHO has been typical. See related story: Stars and Stripes No Longer Flying at WHO – But US Can’t Really Leave Until Dues are Paid, Agency Says US suspension set for next year along with nine developing nations Along with the United States, the draft resolution also noted the suspension by 2027 of nine developing nations due to unpaid dues, including: Burundi, Côte d’Ivoire, Djibouti, Equatorial Guinea, Nigeria, Panama, São Tomé and Príncipe, Timor-Leste, and Turkmenistan. Strikingly, while African delegates urged members to pay their debts, the committee approved the penalty measure without any direct debate or remark regarding Iran or the ongoing US withdrawal. In the morning proceedings, the WHO Secretariat formally proposed amendments, striking Iran from the penalty list, alongside Grenada. “Grenada and Iran, Islamic Republic of, have made sufficient payment to clear their arrears, therefore are no longer at risk of losing voting privileges,” said the WHO Controller during the session. Before the assembly, Iran owed $3.29 million in arrears that triggered an automatic suspension warning under Article Seven of the WHO Constitution. Furthermore, Tehran carried a $7.15 million remaining balance under a special long-term settlement arrangement. However, it remains unclear exactly how much Tehran actually paid, as officials only confirmed the sum was “sufficient” to avert the penalty. According to the draft resolution A79-17, the voting rights of nine other countries, including Afghanistan, Dominica, Myanmar, Saint Lucia, Somalia, South Sudan, Sudan, Venezuela and Yemen were already suspended at the time of the opening of this year’s World Health Assembly, and will remain so until their outstanding dues are paid. Image Credits: Felix Sassmannshausen/HPW. Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Stopping Outbreaks at Source: Pandemic Preparedness Stumbles at Local Level 21/05/2026 Kerry Cullinan Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. The world is not ready for the next pandemic – and it won’t be unless local capacity is strengthened, global health experts agreed at an event in Geneva on Tuesday. Does anyone brief cruise ship captains, cruise operators and passengers from Argentina that hantavirus is an endemic virus? asked Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. “We can have perfect rules, but if we’re not risk-informed, if we’re not alert to the possibility of endemic viruses emerging, none of it is going to count for much,” said Clark, at an event co-hosted by the Independent Panel and the Global Health Centre‘s International Geneva Global Health Platform on Tuesday, alongside the World Health Assembly. Clark stressed that pandemic preparedness involves countries and people knowing their risk: “What are you looking out for? What are you preparing for?” But Dr Mariângela Simão, Brazil’s Secretary of Health and Environmental Surveillance, said that local health facilities “need to have access to diagnostics to help timely intervention”. She noted that hantavirus can be similar to dengue to start with, while dengue, chikungunya, and Zika all have similar characteristics in early infection. The current Ebola outbreak in the Democratic Republic of Congo (DRC) took over a month to detect, with a long journey from “village communities to specialised labs”, said Dr Edem Adzogenu, Global Emissary for the Accra Reset, Africa’s plan to move from aid dependency to health sovereignty. “The inability to detect was simply because of the unavailability of a broad-spectrum diagnostic,” he added. ”What that tells us is, no matter how much preparation you put in place, if it’s not comprehensive, you miss that process. “We’re talking about a country that, since 1976, has had cyclical outbreaks of Ebola, and still does not have the diagnostics to deal with detection at source.” Richard Horton (moderator) and panellists Els Torreele, Dr Mariângela Simão, Maria Guevara and Helen Clark. Mpox response ‘failed miserably’ Els Torreele, an advisor to The Independent Panel, recently completed research into the mpox outbreak – and describes the mpox response as having “failed miserably”. “We need to stop outbreaks when and where they occur, and this is the repeated lesson that we don’t seem to be able to learn,” said Torreele. The world realised that the global stockpiles of smallpox vaccines are effective against mpox – but during the international mpox outbreak in 2022, these were “made available mostly in the Americas and in Europe”, she said, adding that “none of these vaccines actually arrived at the endemic area”. “When the second mpox public health emergency of international concern (PHEIC) was declared [in 2024], we knew there was an effective vaccine, and again it wasn’t made available [immediately],” she pointed out. “WHO pre-qualification was requested, even though the vaccine was registered by the FDA, EMA, and had been shown in the global outbreak to be effective, so delay upon delay.” When vaccines eventually arrived in the DRC and other hot spots, “it was too little, too late because, in an epidemic response, vaccinating the right people at the right moment is critical to curb the pandemic”. Officials in one of the countries affected by the outbreak told Torreele that their vaccines arrived had arrived “when we didn’t have cases anymore”. In addition, only around 23% of all mpox cases were ultimately confirmed in the DRC because it took too long to get samples to Kinshasa and regional capitals for testing. Maria Guevara, international medical secretary for Médecins Sans Frontières (MSF), described the DRC’s health system as “broken”. “If you look at the 2024 national immunisation numbers data, their measles coverage is 55% Why? Because the vaccines aren’t coming there, even if there are existing supplies,” she said, adding that conflict made several areas “inaccessible”, and that there are also “administrative barriers” Two MSF Ebola treatment centres were burnt down in 2019 because community members didn’t trust them, Guevara pointed out. No trust, no PABS agreement Panellists Qatar’s Dr Hanan Al Kuwari, Edem Adzogenu, Global Emissary for the Accra Reset. and WHO’s Olla Shideed. Trust is a key ingredient in pandemic preparedness, said Hanan Al Kuwari, advisor to Qatar’s Prime Minister for Public Health Affairs. The lack of it is hampering agreement on the pathogen access and benefit-sharing (PABS) annex to the Pandemic Agreement. “Trust was weakened and jeopardised by specific facts during COVID-19. When South Africa rapidly sequenced and shared the Omicron variant, exactly what the global health agreements asked countries to do, more than 50 countries responded with immediate travel bans,” said Al Kuwari. “The TRIPS waiver, which could have enabled local vaccine production in the countries that needed it most [during COVID-19], did not receive the support required, reflecting the difficult tensions between global equity commitments and industrial needs. “Vaccines were not distributed equally, and health workers in poor nations went unprotected for months. These are not system failures in the abstract sense. These were decisions whose history sits at the PABS negotiating table with every delegation. That is why regaining trust is not a diplomatic formality. It is the operational precondition for PABS to work.” She described PABS as “the core equity commitment of the entire architecture, which determines whether the country that rapidly shares a pathogen sample will actually benefit from the vaccines and treatments that follow”. Al Kuwari stressed: “Until that is resolved, the agreement cannot be signed or ratified.” The hanavirus outbreak depended on “countries sharing data rapidly and openly, as well as on a WHO that is fully funded and retaining competent staff able to interpret the evidence and inform the decision makers and the public”, she added. Olla Shideed, WHO’s unit head for health emergencies governance, said that 64 countries had spoken in favour of a PABS agreement during a WHA debate on Monday. She, along with Clark, urged countries not to wait for agreement on PABS but to start implementing the Pandemic Agreement. “Speed is of the essence. Speed in detecting speed in surveillance, speed in reporting, and speed in coordinating the action at the national, regional level, and international levels is really what helps us to move forward.” No finances Adzogenu also pointed out that the countries worst affected by the current Ebola outbreak – the DRC and Uganda – have “really serious fiscal constraints” as they are servicing debt. “There’s the manufacturing gap as well,” he said, adding that the Accra Reset aims to ensure that countries have what they need on the ground. Clark said that the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), scheduled for September, could push for the conclusion of the PABS negotiations. “But I think it needs to bang a drum on finance, because we’re talking global public goods here. If a disease gets away, it knows no sovereignty, gender, or whatever. “We need new ways of funding global public goods like preparedness. Some of the bold ideas out there, like global public investment, need member-state champions. “The global public investment model talks about everybody putting into the fund with applications according to need. If everyone’s putting up the money, low-income countries will get more say [in governance].” Image Credits: John Wessels/ MSF. Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pharma Industry Demands Repositioning of Medical Innovation as Strategic Investment, Not Cost 21/05/2026 Felix Sassmannshausen Global health leaders discuss strategic medical innovation. From the left: Isabelle Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche). Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations. GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation of medicines and vaccines can deliver a healthier, stronger future”. “Pharmaceutical innovation has accounted for more than 70% of the increase in life expectancy across G20 and developing countries,” said moderator Isabelle Kumar in her opening remarks. But at the same time, G20 economies are losing an estimated one trillion dollars every year to preventable health conditions, she added. Exploring solutions at scale, the panel keynotes and discussions bridged public, private, and geopolitical sectors. The high-level speakers included Canadian Minister of Health Marjorie Michel and AstraZeneca chair Michel Demaré. They were followed by a panel discussion with Monique Vledder, World Bank Group global director, Florika Fink-Hooijer, Director-General of the EU’s Health Emergency Preparedness and Response Authority (HERA), Penny Heaton of Johnson & Johnson, and Michael Lobritz of Roche. The experts acknowledged that global health architecture currently faces immense strain from escalating vulnerabilities, including ageing populations, antimicrobial resistance, and rising rates of non-communicable diseases. Consequently, leaders urged a major mindset shift, positioning sustained investments in medical innovation as vital catalysts for economic growth. Health investments’ economic potential Despite their differing mandates, the panellists reached a firm consensus: governments must abandon short-term budgeting and invest in medical innovation to secure long-term national resilience and productivity. This demands a profound departure from reactive spending toward proactive strategic investments. IFPMA Director General David Reddy. Echoing this shared conviction during his concluding remarks, IFPMA Director General David Reddy emphasised the overarching economic value of the sector. “Investing in health innovation is not a tradeoff, it’s a multiplier,” said Reddy. To explain the broader economic stakes, the World Bank’s Vledder noted that an unhealthy workforce fundamentally stalls local economies, while funds flowing into the health sector offer tremendous potential for job creation. Industry pushes for tripling of prevention budgets AstraZeneca Chair Demaré reinforced this point, stating that a healthy population experiences fewer sick days and drives higher productivity. He highlighted that establishing a healthy global population could boost the GDP by 7% by 2050 – an economic gain equivalent to the combined economies of Germany and Japan. “So we need a mindset change here to look at medicine and especially innovative medicines as an investment for the future,” said Demaré. Early diagnosis and preventative treatments could drastically reduce long-term hospital costs and boost this overall economic productivity. Currently, OECD countries allocate an average of only 3% of their healthcare budgets to prevention, a figure Demaré argued should double or triple to have a real impact. He emphasised that this shift should rely heavily on functional public-private partnerships, pointing to specific collaborative efforts, such as the Partnership for Health System Sustainability and Resilience, which assesses health systems across more than 30 countries to identify localised governance gaps and propose targeted technological solutions. Canada announces strategic investment Canadian Health Minister Marjorie Michel announced a $131 million public investment into the Pan-Canadian Pharmaceutical Alliance. In the spirit of the industries’ demands, Canada positioned itself as a pragmatic, reliable partner in the global supply chain, navigating amidst geopolitical instability and contrasting its approach with nations relying heavily on threats and tariffs – an indirect reference to the United States under President Trump. “Tariffs are not the Canadian way. Our values are anchored in respect yet viability, predictability and collaboration and the fundamental belief in talent and research,” said Michel. Breaking news on the IFPMA stage, she announced a fresh $131 million injection into the Pan-Canadian Pharmaceutical Alliance. The public investment aims to unify Canada’s fragmented healthcare system into a single market, thereby accelerating drug price negotiations and reducing administrative burdens. The government had also previously announced $1.7 billion to attract world-leading researchers, transforming the nation into a clinical trial powerhouse. By modernising clinical trial frameworks and aligning with international regulators, Canada aims to reduce the time between drug submission and approval by up to 50%. “We need a regulatory system that is timely, predictable, and grounded in science. One that fiercely protects Canadians while giving companies a clear reason to invest in Canada,” said Michel. AstraZeneca Chair Michel Demaré calls for tripling prevention budgets during an IFPMA panel discussion. Europe pivots to security amidst new threats Across the Atlantic, the EU is also heavily investing in its pharmaceutical sector to secure long-term strategic autonomy. Recent legislative moves, such as the Critical Medicines Act, aim to prevent medicine shortages, boost domestic manufacturing, and position the bloc as a global leader by fostering a competitive innovation ecosystem. However, these proactive health initiatives face a formidable obstacle: severe budget constraints compounded by escalating geopolitical conflicts. As financial resources shrink across Europe, medical innovation is increasingly losing critical funding to traditional military priorities against the backdrop of Russia’s ongoing war in Ukraine and increased geopolitical tension. “We had quite a stable budget, and then the political levels decided… we have security as a major risk. So we lost €1 billion… because indeed health got the lower priority,” said Fink-Hooijer. HERA Director-General Florika Fink-Hooijer. To maintain regional production capacity and true preparedness, Fink-Hooijer argued that European officials can no longer view medical innovation merely as an ad hoc healthcare cost. Instead, they must treat it as a foundational pillar of geopolitical defence through structured investments. Reflecting this shift in mindset, HERA actively bridges the gap between health and traditional security by establishing a dedicated unit to monitor advanced biowarfare risks. “We do have now also a civil-military unit in order to really look at that type of threat scenario… because we know that it could also be with AI abuse due to other types of artificial or intentionally produced pathogens,” Fink-Hooijer announced. Meanwhile, restricted public budgets inevitably force regulatory bodies into making high-stakes gambles on future threats. HERA recently directed its scarce resources toward developing a vaccine for the Ebola Sudan strain – a calculated strategic bet that became a bad choice in hindsight, Fink-Hooijer admitted, as it completely missed the current outbreak. Fragility, fragmentation and folly Roche’s Michael Lobritz outlined the industry’s structural vulnerabilities through what he termed the “three Fs”: fragility, fragmentation, and folly. While scientific capabilities accelerate at unprecedented rates and countries compete over production capacities, the global health architecture remains vulnerable to fragmented supply chains. Roche’s Lobritz outlined the industry’s structural weak points through what he termed the “three Fs”: fragility, fragmentation, and folly. He warned that innovation pipelines remain extremely fragile, lacking the investor capital necessary to mature early-stage compounds. Out of 14 viral families with pandemic potential, there are currently only 18 clinical compounds in development, mirroring similar capital shortages in the antimicrobial resistance market. Furthermore, fragmented ecosystems prevent diverse health sectors from coordinating effectively, leading to the dangerous folly of relying on reactive scaling during a sudden crisis without prior preparation. True resilience demands sustained, peacetime collaboration to ensure every therapeutic agent is ready before the crisis hits. Likening the pharmaceutical supply chain to a bustling restaurant kitchen handling a massive dinner rush, he emphasised the vast, unseen preparation required behind the scenes to successfully deliver the final product. “The creation of a novel medicine that changes the course of the life of an individual is not an eventuality or a certainty and needs to be supported,” concluded Lobritz. Addressing the global healthcare gap For this, governments must invest, also to ensure life-saving medical innovation actually reaches the populations that need it most, the participants argued. Outside the IFPMA ballroom, however, health equity advocates caution that framing high-cost pharmaceutical innovation and public-private partnerships as primary drivers of economic resilience can overshadow the need for fundamental strengthening of public health infrastructure, particularly in low- and middle-income countries where access to basic therapeutics remains a major obstacle. The challenge extends far beyond laboratory breakthroughs to the ultimate end-user. Outlining the World Bank’s current attempt to reach 1.5 billion people with essential health services, Vledder acknowledged that scientific innovation means little if delivery systems in fragile states remain broken. Global Health Needs More than Money – Philanthropy Can Amplify Impacts Image Credits: Felix Sassmannshausen/HPW. Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Russia Tries to Block Debate on Attacks on Health Facilities in Ukraine 20/05/2026 Disha Shetty Interior of a hospital room in Kherson heavily damaged during conflict, showing extensive structural destruction and debris. Neither Russia’s delegate banging her desk to interrupt Ukraine’s representative speaking at the World Health Assembly (WHA), nor her request to dismiss debate, stopped member states from condemning Russia’s attacks on Ukraine’s health system. A report by the World Health Organization’s (WHO) Director-General before delegates estimated that Russia’s aggression on Ukraine has caused 55,600 civilian casualties, including 14,999 deaths. Violence intensified in 2025 with civilian casualties going up by 31% compared to the previous year, and by 70% when compared to 2023. The WHO also documented 579 attacks on healthcare facilities that caused 19 deaths and 204 injuries among healthcare workers and patients in 2025. This was an 18% increase compared to 2024. “Since this report was published, WHO has recorded 190 new attacks on health care, with 86 injuries and 15 deaths between 1 January and 6 May, 2026,” said Dr Altaf Mossani, Director of Humanitarian Disaster Management, WHO Emergency Preparedness and Response program. “On May 14, a clearly marked United Nations vehicle was severely damaged by drone strikes in Kherson City. This is the second incident that week,” he added. Russia targeting healthcare infrastructure The 79th World Health Assembly in session. Countries raised alarm at the WHA that 202 of Ukraine’s 11,887 health facilities have been severely damaged, and 1,013 units are partially damaged. “We strongly condemn Russia’s ongoing war of aggression against Ukraine and the deliberate escalation of attacks targeting civilians and civilian infrastructure, including health care facilities, and we are deeply alarmed by the sharp increase in attacks on the health infrastructure since the last World Health Assembly,” Moldova’s representative told the WHA. Civilian attacks also drew sharp criticism, leaving Russia isolated during the discussion. “Russia’s attacks on energy infrastructure and other civilian targets, such as hospitals, elderly homes, or kindergartens, became increasingly vicious and brutal,” said Germany’s delegate. “On average, it has been said already, there have been more than 3,000 Russian attacks directly affecting health care institutions, two each day.” Ghana empathised with countries that are receiving a large number of refugees from Ukraine as a result of the conflict, resulting in an additional burden on their health systems. High drama by the Russian representative Russia’s representative to the WHA banged the desk to interrupt Ukraine’s speaker and called the WHO’s report on the health situation in Ukraine “disinformation.” Russia’s representative first moved to dismiss the debate on the report on Ukraine entirely. That request was put to a vote and defeated. Following extensive discussion on the report, Russia again moved to stop the WHA from noting the report. Russia was reminded that noting the report was merely procedural, but it requested a vote again. Once again, countries voted in favour of noting the report. At one point, the Russian representative banged the desk several times to interrupt the Ukrainian speaker, and was reminded to raise the country’s flag if she wanted to make a statement. Russia then accused the WHO of spreading misinformation. “WHO is talking only about attacks on Ukraine, ignoring the information that has been submitted to WHO on attacks on Russian facilities. So, we would ask WHO to stop misleading the world and to stop disseminating misinformation when it comes to voting on this report,” the representative accused. WHO’s report noted that there were 21 attacks on healthcare facilities in Russia, causing 17 injuries. Russia did not agree with this number. However, the Russian representative said, “more than 250 Russian facilities were attacked by Ukraine, and only 35 of them have been officially reported by WHO. And indeed, in the report, even that figure has deliberately been lowered”. Russia opposed the noting of the report by the WHA. The report was noted nevertheless, following a vote. Polio needs attention Polio remains endemic in the WHO’s Eastern Mediterranean Region (EMRO) region. WHA also discussed polio that remains an issue in several countries like Pakistan and Afghanistan. Conflicts and funding cuts have in recent years interrupted polio vaccination campaigns. In Gaza, polio made a resurgence as conflict raged. Most of these areas fall under the WHO’s Eastern Mediterranean Region (EMRO) region. “We are actually the last part of the world where that virus remains endemic, but we are doing our utmost to tackle this issue. We have seen, however, that in Afghanistan and Pakistan there have been declines in transmission trends, and we think that is a cause for optimism about wild polio virus transmission,” Libya said, making a statement on behalf of the EMRO region. Other countries reminded the WHA that polio is still a relevant issue that needs attention. “We wish to recall that polio is still a global health challenge because new cases of wild polio have been recorded in certain countries, and there are new coast cases in conflict areas. Then, hence, the need for further international effort to ensure that we have national and regional preparedness,” Oman’s representative told the WHA. Also read: Polio Eradication Imperiled by $2.3 Billion Funding Gap Image Credits: WHO Ukraine, X/WHO, WHO. WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO: Ebola Outbreak Is a Deadly Regional Threat But Not a Global Pandemic Risk 20/05/2026 Stefan Anderson The WHO has determined that the Ebola outbreak raising alarm worldwide does not pose a pandemic threat. GENEVA — The Ebola outbreak unfolding in the Democratic Republic of Congo (DRC) and Uganda poses a “low” risk globally, according to an expert committee of the World Health Organization (WHO). However, the national and regional risk is “high”, according to the International Health Regulations (IHR) Emergency Committee. Last Sunday, WHO Director-General Dr Tedros Adhanom Ghebreyesus had already declared the outbreak a public health emergency of international concern (PHEIC), the WHO’s second-highest level of alert, before convening the emergency committee. This is the first time in WHO’s history that this has occurred. Tedros was motivated by the scale and speed of the spread of the Bundibugyo virus, a rare and particularly deadly strain of Ebola, which has killed at least 131 people and infected over 500 others. The emergency meeting, convened on Tuesday to assess the threat of the current outbreak, concurred that the situation is a PHEIC but “not a pandemic emergency,” Tedros told a media briefing on Wednesday. The committee, chaired by Professor Lucille Blumberg, agreed with the Director-General’s assessment and is finalising its recommendations in the coming days. “Our prime aim was to support the decision and decide whether this is a public health emergency of international concern, and to consider whether there’s a pandemic emergency. The former was agreed to,” Blumberg said. Investigations into the outbreak’s origin Anaïs Legand speaking at the emergency press conference on the Ebola crisis. “Investigations are ongoing to ascertain when and where exactly this outbreak started,” said Anaïs Legand, a technical officer for high-threat pathogens at WHO’s health emergencies programme. “Given the scale, we are thinking that it has started probably a couple of months ago, but investigations are ongoing, and our priority is really to cut the transmission chain by implementing contact tracing, isolating and caring for all suspect and confirmed cases.” The Bundibugyo species was last seen in 2007, and there is currently no vaccine or treatment licensed for it. Investigators say the true scale of the epidemic in DRC is much larger than current case counts suggest. War, and a very long drive Dr Mohamed Yakub Janabi, WHO’s regional director for Africa. WHO officials laid out several reasons the outbreak escaped detection. The province of Ituri, where it emerged, is engulfed in war. Fighting between the DRC army and the M23 armed group has intensified in recent months, displacing more than 100,000 people. Beyond the conflict, eastern DRC is among the most challenging places in the world to mount a public health response. Health facilities are sparse, roads are limited, and much of the terrain is forested and mountainous. A previous Ebola outbreak in the same region in 2018-19 took close to two years to bring under control, even with a licensed vaccine available. Dr Mohamed Yakub Janabi, WHO’s regional director for Africa, said the combination of factors made early detection enormously difficult. “Detecting outbreaks such as Ebola in a complex setting like Ituri province in the DRC is inherently challenging,” he said. “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partner coordination.” Samples from the outbreak zone must travel 1,700 kilometres to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The distance to the capital is comparable to London to Warsaw – a roughly a 24-hour drive on smooth European roads, a far cry from the remote jungle tracks and dirt roads of Ituri. “In remote or insecure areas, it can take time for cases to be recognised and samples transported,” Janabi said. Symptoms mistaken for endemic diseases Nearly 7 tonnes of emergency medical supplies and equipment along with a team of 35 experts from WHO and the DRC’s health ministry, arrived today in Bunia from Kinshasa to support frontline #Ebola response in Ituri Province. The Bundibugyo strain’s early symptoms also overlap with diseases endemic to eastern DRC, leading health workers to mistake initial cases for more common illnesses. “Nonspecific early symptoms, for instance, if you take malaria and typhoid, the early symptoms are the same,” Tedros said. “The region is very endemic to those diseases, so the health workers will associate the early signs with malaria or typhoid, and they can’t diagnose based on the symptoms. They may start treating that.” Dr Abdi Mahamud, WHO’s director for health emergency alert and response operations, said the diagnostic challenge would have tripped up better-resourced systems. “This outbreak is happening in a highly endemic [setting for] other diseases that present similar symptoms – malaria, dysentery, and others,” he said. “If you don’t have that high index of suspicion, if you don’t have the right facility to test, even in high-income countries, you will have that delay in the start of an outbreak.” Diagnostic tests routinely used across the region added another layer of delay. The Bundibugyo strain belongs to a different genus, Orthoebolavirus, than the more common Zaire strain that most existing tests are optimised to detect. “There was a problem linked to the traditional test we use,” Tedros said. “The traditional test is optimised with Zaire, and the same sample was taken and tested, but since the test kit is optimised with Zaire, [Bundibugyo] could not be detected.” No vaccine, but a pipeline Vasee Moorthy, WHO’s research and development lead on the current outbreak, laid out the state of the vaccine pipeline for the Bundibugyo strain. The Bundibugyo strain has no licensed vaccine or therapeutic. WHO’s research and development lead, Vasee Moorthy, said a pipeline of candidates is being accelerated but remains months away. Moorthy said the most promising candidate is an rVSV Bundibugyo vaccine, the equivalent for this strain of Ervebo, the licensed Merck vaccine used against the more common Zaire Ebola strain since 2019. “There are no doses of this which are currently available for clinical trial, so this needs to be prioritised,” Moorthy said. “The information that we have is that this is likely to take six to nine months.” A second candidate, built on the ChAdOx1 platform used in the AstraZeneca COVID-19 vaccine, is being developed by Oxford and the Serum Institute of India. “They are manufacturing that as we speak, but there is no animal data to support [its efficacy],” Moorthy said. “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty about that.” Even in the most optimistic scenario, neither candidate is likely to be available to materially shape the trajectory of the current outbreak. In the meantime, the response is being built around the basics: safe treatment centres, patient referral pathways, contact tracing, and the protection of health workers, among whom the first confirmed case in the outbreak was identified. “The protection of healthcare workers and families is absolutely paramount,” Blumberg said. “The people in the area and those who respond need to be kept safe and allowed to be able to do what they need to do in a critical time such as this.” Tedros: Rubio suffers ‘lack of understanding’ US Secretary of State Marco Rubio. The WHO chief used the press conference to push back at US Secretary of State Marco Rubio, who said this week the agency had been “a little late to identify this thing.” The US has banned citizens of the DRC, Uganda and Sudan from entry, closed its only dedicated Ebola lab, withdrawn from the WHO, and defunded the agency. “On what the Secretary said, it could be from a lack of understanding of how IHR works, and the responsibilities of WHO and other entities,” Tedros said. “We don’t replace the country’s work, we only support them, so that’s why there could be some lack of understanding.” Tedros suggested conflict in the affected region was a more fundamental factor in the delay than anything WHO could have done differently. “Health facilities cannot work optimally when there is conflict and when the health workers are also fleeing as part of the community which is displaced,” he said. “It affects the whole surveillance system, and not only that, but it also affects access.” “I think that’s what we should understand, the secretary or others.” Asked repeatedly whether US funding cuts to DRC surveillance programmes had contributed to the outbreak going undetected, Tedros declined to draw a direct line. “We don’t need to jump to conclusions before we understand the whole complexity. It would be very difficult to associate it with funding alone,” he said, noting that the diagnostic gap was a question of the wrong tests being administered rather than supply. Legand echoed the point, noting the issue stems from test type, not supply: “For the time being, it’s not a supply issue. We need to ensure that the right platform with the right data arrives at the right place. This is the work that is being done as we speak.” The outbreak, meanwhile, continues to spread through a war zone with no vaccine, no cure, and a diagnostic system still catching up to the strain it now faces. Image Credits: @WHO African Region, Gage Skidmore. Posts navigation Older posts